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Abstract
Emily Dean
AN IN SILICO STUDY OF THE DELTA OPIOID RECEPTOR USING SMALL
MOLECULES
2020-2021
Chun Wu, Ph.D.
Master of Science in Pharmaceutical Sciences
The DOR is the least studied out of the three opioid receptors (µ, κ and 𝛿). The
most is known of the Mu Opioid receptor (MOR) and the drugs that target it have led to
the global opioid epidemic due to their adverse effects of tolerance and addiction. The
DOR is not known for the same adverse effects and therefore, is a promising
pharmacological target for the development of new opioid ligands. In this thesis,
molecular modeling, simulations and other computational methods are introduced in
Chapter 1 where these methods are used to study the activation mechanism of DOR
(Chapter 2) and are used to identify novel DOR agonists (Chapter 3). Recently, both the
inactive and active conformations of the DOR have been solved. However, the activation
mechanism remains to be elusive. In Chapter 2, molecular dynamics (MD) simulations
will offer a deeper insight into the dynamics and interactions beginning with the inactive
conformation of the receptor when bound to an agonist undergoing a conformational
change. Chapter 3 will involve the use of high-throughput screening of new molecules for
potential agonist candidates using multiple conformations of the active conformation of
the DOR. The top lead compounds subjected further computational analysis on their drug
properties to ensure that they do not cause any unwanted side effects. Final lead
compounds are available for experimental testing.
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Chapter 1
Introduction to Molecular Dynamic Simulations
1.1 Background
The detailed molecular information on the drug targets are not used in traditional
developmental methods of new drugs. Consequently, when a new drug is brought into the
market using the traditional developmental methods, the money, amount of time needed,
and risk of failure can be very costly, taking anywhere from 10-15 years from the initial
identification until the drug is developed and on the market, in addition to costing
between 800 million to 1.8 billion US dollars1. The increase in databases and the genomic
and protein information plus an advancement in computational methods, with higher
performance and better algorithms to process these valuable information greatly advances
the drug discovery process2, 3.
Computational tools used for the discovery and development of a new drug to aid
in human health range from a number of applications and methods. Computer aided drug
design (CADD) is a powerful application that has been developed that uses the rational
drug design approach that provides more knowledge and information about binding
affinity and any interactions in the protein-ligand complex1. The use of this tool has
enhanced the preliminary stage of the drug discovery process by reducing the failures of
potential molecules at the drug development level to be brought onto market, as well as
minimizing the cost. CADD consists of two general approaches: structure-based and
ligand-based. Both of these methods have made their own advancements without the
other.
1

Structure-based drug design (SBDD) begins with identifying and processing the
desired three-dimensional (3D) target with all of its structural information4. By using a
3D structure of the protein target, this allows for the use of computation to delve into
experimental results at the atomic level and to gain more understanding of disease at the
molecular level. This target structure can be taken from a variety of different methods
such as experimental methods like NMR and X-ray crystallography downloaded to a
database, or purely computational methods like homology modeling and molecular
dynamics (MD) simulations. SBDD can be divided into two subcategories within itself:
the de novo approach and the virtual screening approach. The de novo approach produces
some lead compounds, but mainly offers new scaffolds of ligands that can be further
developed due to their attractive properties by using fragments of molecules that
correspond with the binding site1, 5. The idea is based on the primary constraints of
ligands and receptors that are already known to produce novel compounds. The virtual
screening (VS) approach uses commercially available small molecule libraries to identify
compounds predicted to have attractive binding affinities for the target protein of a
known structure. Once these compounds are identified, it is with the thought that they
will then be experimentally tested on. This method does not produce novel ligands.
Ligand-based drug design (LBDD) is the method of CADD that is useful when
the desired protein target is missing important structural information or when its entire
3D structure itself is absent6. If this is the case, the approach is to use the information
from the known ligands that bind to the target of interest to determine the lacking
structural and/or physiochemical information causing the observed biological response1.
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LBDD utilizes two approaches: quantitative structure-activity relationships (QSARs) and
pharmacophore-based techniques.
Molecular dynamics (MD) simulations is a computational technique that further
enhances the drug design process. It is used to simulate a molecular system in a period of
time to study the interactions and stability based on the physical laws.7 This technique
can help rule out ligands that will not remain stable in complex with the target. This only
adds more insight into the interacting behavior of a ligand with its target in higher special
and temporal resolution than traditional experimental methods.
Because of the advancement in computational methods with higher performance
and better algorithms, the preliminary stage of the drug discovery process has become
much more reliable with higher accuracy and less costly procedures3. This is largely in
part due to the vast availability of both genomic and protein information, as well as the
access to computational tools and applications such as ligand design, modeling,
pharmacophore mapping, protein-ligand molecular dynamic simulations, and toxicity
predictions.
1.2 Methodology
1.2.1 Homology Modeling
To study a protein, whether it be the protein’s dynamics or finding ligand
candidates, the three-dimensional (3D) structure of the protein is typically required.8, 9
The 3D structure is determined from the protein sequence. Experimental methods such as
NMR spectroscopy and X-ray crystallography are how protein structures are determined
but both methods are time consuming and cannot necessarily be used for each protein. In
3

the case of NMR spectroscopy, the protein molecules generally need to be smaller and
with X-ray crystallography, the molecules need to be crystallized. There are difficulties
when it comes to protein purification and crystallization, most notably in membrane
proteins that make up a majority of therapeutic targets, which causes a deficiency in high
resolution 3D protein structures.
Homology modeling is considered to be a powerful computational prediction tool
with two main observations: the 3D protein structure is determined precisely by its amino
acid sequence, and protein structure is very conserved with change happening at a slow
rate.8 It is also fast with low cost and simple steps. There are seven standard steps with
this modeling method: (1) The identification and the selection of templates using
sequence similarity as well as environmental and phylogenetic factors, (2) Sequence
alignment with careful inspection and alignment correction, (3) Model building, (4) Loop
modeling with accuracy determining the significance of the model for future use, (5) Side
chain modeling using the backbone, (6) Model Optimization to improve the model
quality, (7) Model Validation where the functionality is determined by the quality of the
model.
1.2.2 Molecular Docking and Structure Based Virtual Screening
Molecular docking is a key tool used in the drug discovery process due to its fast
and cost-efficient methodologies that predict the binding pose of ligands to the active site
of their respective targets. Docking has been a great help with screening large libraries of
molecules, meaning it has the ability to work in combination with structure-based virtual
screening (SBVS). This works by docking large libraries of small molecules to a target in
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a short time frame. The docking software generates a molecular surface of the target
structure on the basis of high-resolution structure that achieves the docking poses.
Spheres are generated in a known ligand binding site of the target and determine all the
possible orientations of new ligands. A scoring function is then used that ranks the
different poses by most favorable to least favorable binding. Docking has three main
scoring functions. The force-field based approach is the first that is based on
experimental data that estimates binding affinity. Empirical scoring has a simplified
version of the parameters in the force-field based approach that gives slightly less
accurate results. The knowledge-based scoring function is the third approach that is taken
from known binding interactions and is more common than using random distribution.
After filtering by docking score functions, ADMET(absorption, distribution, metabolism,
excretion and toxicity) property prediction is utilized for SBVS by providing insight into
different relevant properties that tell if a molecule is druggable. About half of the
potential drugs tested fail in clinical trials due to poor ADMET properties, making early
prediction cut out a lot of time and cost that would be wasted on testing unnecessary
ligands. Schrodinger’s Glide extra precision (XP) docking uses extensive algorithms that
uses not only water desolvation energy terms, but also QikProp ADME prediction.
XP Glide Score = ΔEcoul + ΔEvdW+Ebind +Epenalty
Ebind=Ehyd_enclosure4+Ehb_nn_motif5 +Ehb_cc_motif6 +EpI7 + Ehb_pair +Ephobic_pair
Epenalty = Edesolv +Eligand_strain

5

1.2.3 Molecular Dynamics Simulations
Molecular dynamics simulations are a technique that uses the integration of Newton’s
equations of motion.7 The purpose is to simulate behaviors of a dynamic molecular
system throughout a period of time. Using the Newton’s laws of motion, MD simulations
predict the motions of the atoms when acted upon by forces. The forces that are
calculated in these simulations are based on force fields, which are the equations used to
set up parameters that determine the potential energy interactions of the system. These
interactions and features include bond rotations, bond length, and Coulomb’s law,
comprising of van der Waals and electrostatic interactions.10 There are two different
solvent models to simulations that have different levels of atomic detail. Explicit solvent
models are effective by imitating the most realistic solvent effects but are high in cost.
This type of model is better for comparing drastically different systems. Implicit models
use a dielectric constant and treat the solvent as a continuous medium, making it cheaper
to use and a better option for comparing systems that are more similar to each other.
After the system is prepared, the simulation is ran and reaches equilibrium, snap shots are
taken throughout the simulation time, creating the simulation trajectory. The position of
all the atoms in the system have coordinates that are contained in each of the snap shots.
Using this, different post simulation analyses can be performed to help determine the
questions asked beforehand. Trajectory clustering is one of the analyses performed postsimulation to identify the populated conformation by first aligning each snapshot of the
trajectory. After the initial alignment, the different populated clusters are based on the
root mean squared deviation (RMSD) of the backbone of the target protein to determine
structural similarity and represent the different structural families. The populated
6

conformations generated can then be used as the most ideal binding positions of the
target.
1.2.4 MM-GBSA/MM-PBSA Binding Free Energy Calculations
To determine if a bound ligand is stable in its target’s binding pocket, the binding
free energy during the simulation can be calculated. There are different prediction
methods of binding free energy, however, the end point methods have been particularly
useful by calculating the bound and unbound states of solvated molecules.11 The two
known end point methods are the molecular mechanics generalized Born surface area
(MM-GBSA) and molecular mechanics Poisson-Boltzmann surface area (MM-PBSA).
These binding free energy methods are fast and widely exploited.12 The calculations are
done through minimization on the receptor alone, the ligand alone, and then the receptorligand complex. There are three components involved in the energy decomposition of
these calculations which are van der Waals, electrostatic, and hydrophobic interactions
using surface area. Each component contributes to the final result of the total binding
energy. This gives further insight into the most optimal binding conformation of the
ligand in the binding pocket. The calculations of binding free energy do not include a
solute entropic term; therefore, the true binding free energy could be much lower. This is
compensated for when different binding poses have comparable solute entropies to each
other, allowing the relative binding free energy to be relative to MM-GBSA binding
energies. In the equations, the internal energy change (ΔEint) is canceled due to the
receptor and ligand being extracted from the same trajectory. This makes the electrostatic
(ΔEELE) plus the van der Waals (ΔEVDW) energies equal to the gas phase interaction
energy (ΔEgas) from the receptor and ligand. In the fourth equation, polar and nonpolar
7

energy terms together make up the solvation free energy (ΔGsol). While the polar
contribution (ΔG(GB)) is calculated using the GB model, the nonpolar energy term
(ΔG(Surf)) is calculated using solvent-accessible surface area. Because the entropy term is
neglected, the binding free energy (ΔGbind) is the sum of the gas-phase and solvation free
energy.
ΔGbind = (Gcomplex) – (Greceptor) – (Gligand)

(1)

ΔGbind = ΔH - TΔS ≈ ΔEgas + ΔGsol – TΔS

(2)

ΔEgas = ΔEint + ΔEELE + ΔEVDW

(3)

ΔGsol = ΔG(GB) + ΔG(Surf)

(4)

1.3 Thesis Outline
In Chapter 2, the activation mechanism of the Delta Opioid receptor (DOR) was probed
using novel agonist ADL5859 in multiple microsecond molecular dynamics simulations.
Out of the three opioid receptors, (Mu, Kappa, Delta) the Delta receptor is the least
studied with the potential for reduced adverse side effects. Recently, crystal structures of
both the inactive and active conformation of the DOR were solved. However, the
activation mechanism for this specific receptor remains elusive. To give deeper insight
into what the activation mechanism may be, we started with a homology model of the
inactive conformation of the DOR and docked the agonist ADL5859 into the binding
pocket before starting the 1 microsecond MD simulations. Because all crystal structures
contained fusion proteins at the N terminus, they were removed to rule out any
probability that they may have played a role in the conformational change. The crystal
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antagonist Naltrindole was also used and underwent 1 microsecond MD simulations to
serve as an inactive control to compare our active complex. The most notable difference
between the active and inactive state of class A GPCRs is the outward movement of
transmembrane 6 (TM6) that opens up the intracellular portion of the receptor to allow G
protein signaling and ultimately activation. After performing the MD simulations on both
ligand complexes, the outward movement of TM6 was observed in the agonist bound
complex. Additional analyses were performed including the molecular switch analysis
and measuring the center of mass distances of known residue contacts for class A GPCRs
and other unique distances to this study. Through our findings, key residues were
identified that played a role in the activation of the DOR using an agonist starting with
the inactive state of the receptor. In Chapter 3, HTVS coupled with MD simulations were
used to find potential agonist candidates targeting the DOR. The world still struggles with
opioid addiction. Addiction is a side effect found in agonists that target the MOR. The
DOR has shown to not have addictive properties, indicating that finding ligands that
target this receptor while eliciting the biological response of antinociception is of high
importance. The HTVS and MD simulations were not just run on the active
conformation, but on two other active conformations found while simulating the active
crystal DOR with the crystal agonist ligand, making this an ensemble-based approach.
The reasoning for this is due to the flexibility of receptors creating challenges within the
binding site with amino acid side-chains that have dozens of rotatable conformations. The
ensemble-based approach samples the degrees of freedom of the side chains instead of
using just one conformation. The HTVS was ran on the multiple conformations and the
top molecules were simulated to assess their stability. Through this and additional
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analyses, 8 compounds were identified that should be considered for experimental
testing.
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Chapter 2
To Probe the Activation Mechanism of the Delta Opioid Receptor by an Agonist
ADL5859 Starting from the Inactive Conformation Using Molecular Dynamics
Simulations
2.1 Introduction
2.1.1 Problems With Opioid Receptors
Ligands that bind to receptors are typically classified as an agonist or antagonist,
meaning they either elicit a biological response or they block the response, respectively.
Opioid receptors, members of G-protein-coupled receptors (GPCR), bind an agonist such
as opioids outside the cell and adopt the active conformation to activate G proteindependent signal transduction pathways, ultimately, inducing the biological response of
antinociception.13, 14 There are three types (µ, 𝛿 and κ) of opioid receptors (MOR, DOR
and KOR)15, all exhibiting antinociceptive properties. There is a fourth opioid receptor,
nociception/orphanin (NOR) that little is known about. However, it is thought that due to
its location in the brain and spinal cord that it’s activation can be similar to MOR effects
or sometimes oppose them.16 Among them, MOR is the major pharmacological target of
current opioid drugs such as morphine. However, these drugs targeting MOR are known
for their high propensity for abuse and tolerance, leading to the current opioid epidemic
in the United States and the rest of the world. Thus, there is pressing need to develop
non-MOR-based opioid drugs. While drugs acting at the KOR produce dysphoria and
anhedonia17, 18 19, 20, these same adverse effects are not observed when testing drugs that
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act at the DOR. This makes the DOR a promising pharmacological target for developing
new opioid drugs for pain medication.21
2.1.2 History of DOR Agonists
Over the years, researchers have been able to produce agonists that can target the
DOR and cause antinociception and/or antidepressant-like effects without adverse
weight-based effects.22-24 However, these molecules caused convulsant activities in vivo,
making the search for an optimal agonist for the DOR continue. Through trial and error,
ADL5859, a small molecule agonist targeting the DOR has been discovered with
promising properties, including no adverse effects on convulsant activities. This ligand
completed phase I in clinical trials, showing it was well absorbed after oral administration
and was generally well tolerated, ready to move on to phase II.25 While this drug has
shown promising activities in vivo, there is no crystal structure of ADL5859 with the
DOR. Because of this, the detailed interaction of this ligand with the receptor is
unknown, as well as the activation mechanism.
2.1.3 Crystal Structures and Previous MD Simulation Studies of the DOR
Recently, three crystal structures of the DOR have been solved; one is of the
inactive state receptor with an amino terminal b562RIL fusion protein in complex with the
antagonist, naltrindole (PDB ID: 4N6H), and two structures are of the active state DOR
with the peptide agonist KGCHM07 (PDB ID: 6PT2) and with the small molecule
agonist DPI-287 (PDB ID: 6PT3), both with a b562RIL fusion protein that contained three
point mutations. When aligning the crystal structures (Figure A1), the two agonist bound
complexes (6PT2 & 6PT3) show significant overlap, but in contrast, the antagonist
12

complex (4N6H) shows great differences mainly in the fusion protein, as well as TM5,
intracellular loop (ICL) 3, and TM6. The difference in transmembrane (TM) 6 between
the crystal structures appears to be one of the molecular switches in GPCR activation
known as the Transmission Switch, and is a hallmark of GPCR activation, indicating the
agonist bound complexes as the active crystal structures and the antagonist bound
receptor as the inactive crystal structure. However, because the fusion protein also adopts
very different conformations in the two complexes, the probability of the fusion protein
causing the conformational change of TM6 cannot be completely ruled out. Because both
DPI-287 and ADL5859 share the same pharmacophore and biological activity, their
action on the DOR should be similar (Figure 1).

Figure 1
Chemical Structures of Agonist ADL5859, Agonist DPI-287, and Antagonist Naltrindole
to DOR

ADL5859

DPI-287
Naltrindole

Note. Pharmacophore of agonists highlighted in pink to show similarity.
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The DOR has not been as well studied as the MOR and KOR. With computational
research on the rise, studies were conducted that modeled the DOR even before a crystal
structure was available using templates such as bovine rhodopsin. Through this and a 20
ns molecular dynamic (MD) simulation, it was suggested that between residues D128 and
R192, an internal salt bridge exists. Another study delved into the possible interfaces of
DOR homodimeric complexes26, 27. After solved crystal structures of the DOR became
available, a study that solved two DOR crystal structures themselves modeled the active
state DOR and docked small molecules and peptides into their crystal structure to
evaluate water-mediated interactions in the binding pocket.28 Although the motion of
TM6 is a known hallmark of activation for GPCRs, the key change at the residue level is
not known for the DOR. Recently, a study 29 has suggested an activation pathway for β2adrenergic receptor, M2 muscarinic receptor, µ-opioid receptor, k-opioid receptor, and
adenosine A2A receptor. However, the DOR has not been confirmed to have this pathway,
leaving its activation pathway unknown.29
2.1.4 Experimental Overview
To give a better insight and understanding of the activation mechanism and
detailed interaction of an agonist with the DOR, we ran multiple 1s molecular dynamic
simulations of the novel ADL5859 and of naltrindole starting with a homology model of
the inactive DOR (4N6H). Starting with the inactive conformation and an agonist allows
us to probe the conformational change of the receptor toward the active conformation
through MD simulations, giving insight into a potential activation mechanism for the
DOR. To rule out the probability of the fusion protein causing the conformational
change, it was removed. The ADL5859 was first docked to the inactive receptor
14

homology model and this initial structure was used for the simulations. Our most
abundant structure from our MD simulation was then compared to the active state crystal
complex to find the similarities and differences in the protein-ligand binding interactions
and dynamics between the two systems. We observed TM6 move outward with a
favorable overlap of our complex with the agonist bound crystal complex, supporting the
evidence of the molecular switches for this receptor, specifically the Transmission
Switch. Center of mass distances were measured as well using known residue contacts for
some class A GPCRs as well as unique distances to our study to determine the
conformation change occurring after beginning with the inactive state. The motion of
TM6, as well as our additional distance analyses, offers insight into the activation
mechanism of the DOR bound with agonist ADL5859. Given the hallmark movements
and known residues, we believe our simulation has reached the active-like conformation.
Our findings allows for an experimental mutagenesis study using our key residue
pathway. The detailed interaction of ADL5859 with the DOR will also help to develop
the opioid class of drugs.
2.2 Methods
2.2.1 Multiple Sequence Alignment and Analysis
Conservation of residues among 62 members of class A GPCR was investigated
using Jalview program30. Protein sequences of 61 class A GPCRs listed in the GPCREXP database (https://zhanglab.org/GPCR-EXP/) and 5 class A GPCRs listed in the
subfamily A4 of rhodopsin family in the Pfam database
(http://pfam.xfam.org/family/PF00001) were retrieved from the UniProt database and
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MUSCLE tool31 with default settings was used for the multiple sequence alignment.
Positional occupancy of each residues was analyzed at both family and subfamily levels.
2.2.2 The Homology Modeling of the DOR
The FASTA files of human DOR-1(P41143) were obtained from the UniProt website to
fix any nonnative mutations.32 The sequence is shown in Figure A2.33, 34 The Prime
feature in Maestro35, 36 was used to build the homology model based on pre-aligned
crystal structure of human δ-opioid 7TM receptor bound with antagonist naltrindole
(PDB ID: 4N6H) oriented in the membrane from the OPM web server site. 37 The crystal
structure of human δ-opioid 7TM receptor bound with with agonist DPI-287 (PDB ID:
6PT3) was used for comparison. Alignment is based on the backbone residues of TM15&7 (4N6H: 39-77, 82-111, 117-152, 161-187, 206-243, 293-321; 6PT3: 45-77, 82-111,
117-152, 161-187, 206-243, 293-321).
2.2.3 Molecular Docking of ADL5859
Protein structures were prepared using Maestro’s Protein Preparation Wizard.38
The charge state of the preprocessed protein was optimized at pH 7. A restrained
minimization was then performed to relax the protein structure using OPLS3 force
field.39 The 3D structures of naltrindole and ADL5859 were prepared using Maestro
Elements. Figure 1 shows the chemical structures of the ligands. The 2D structure of
ADL5859 was drawn using Maestro’s 2D sketcher, converting into 3D structure. 3D
structure of naltrindole was extracted from the crystal structure (PDB ID: 4N6H). Both
ligands had their bond orders fixed and underwent the pKa calculation. The
ionization/tautomeric states were generated at pH 7 using Maestro’s Epik tool based on
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the more accurate Hammet and Taft methodologies.38 The lowest ionization/tautomeric
state (+1) was selected and the geometry was then minimized to the most energetically
favorable structure to relax the structure of the ligand.
The receptor grid files were generated from the prepared receptors, in which the
centroid of the crystal ligand, naltrindole, was used to specify the active site. The
prepared ligands (naltrindole and ADL5859) were docked into their corresponding
generated grids using Glide XP scoring with default procedures and parameters.40, 41 In
detail, the receptor grid required for the docking process was generated using van der
Waals scaling factor of 1 and partial charge cutoff 0.25. Docking was performed using a
ligand-centered grid using OPLS3 force field.39 Glide XP Dock performed a
comprehensive systematic search for the best receptor conformations and orientations to
fit the ligand. The docked poses were compared to the inactive crystal complex (PDB ID:
4N6H) with an antagonist to verify if the docked ligand poses were reasonable. Both
ligands were bound within the binding pocket with naltrindole binding similar to the
crystal ligand with subtle differences, providing a reasonable starting pose for later
molecular dynamic simulations. The binding pose can then be refined given the full
conformation flexibility in the simulations.
2.2.4 Molecular Dynamics Simulation System Setup
Two MD simulation systems were constructed using the prepared and refined
receptor-ligand complex from the Glide XP docking and crystal structure (4N6H) as
input files. Each system was built using SPC as water solvent model 42 using
orthorhombic solvent box with 10Å water buffer. System was neutralized using Na+ and
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Cl- ions and were added to maintain the salt concentration of 0.15 M NaCl. After the
system was successfully solvated, OPLS3 force field39 was used to represent the receptorligand.
Using Desmond module, the system was first relaxed using the default relaxation
protocol for membrane proteins.43 This relaxation protocol consists of eight stages: 1).
Minimization with restraints on solute heavy atoms; 2). Minimization without any
restraints; 3). Simulation with heating from 0 K to 300 K, H2O barrier and gradual
restraining; 4). Simulation under the NPT ensemble (constant number of particles,
constant pressure of 1 bar and constant temperature of 300 K) with H2O barrier and with
heavy atoms restrained; 5). Simulation under the NPT ensemble with equilibration of
solvent and lipids; 6). Simulation under the NPT ensemble with protein heavy atoms
annealing from 10.0 kcal/mol to 2.0 kcal/mol; 7). Simulation under the NPT ensemble
with Cα atoms restrained at 2kcal/mol; and 8). Simulation for 1.5 ns under the NPT
ensemble with no restraints. After the relaxation, three trajectories (1000.0 ns of each)
were conducted under the NPT ensemble for each of the systems using the default
protocol. In details, temperature was controlled by using the Nosé-Hoover chain coupling
scheme 44 with a coupling constant of 1.0 ps. Pressure was controlled using the MartynaTuckerman-Klein chain coupling scheme 44 with coupling constant of 2.0 ps. M-SHAKE
45

was applied to constrain all bonds connecting hydrogen atoms, enabling a 2.0 fs time

step in the simulation. The k-space Gaussian split Ewald method 46 was used to treat
long-range electrostatic interactions under periodic boundary conditions (charge grid
spacing of ~1.0 Å, and direct sum tolerance of 10-9). The cutoff distance for short-range
non-bonded interactions was 9 Å, with the long-range Van der Waals interactions based
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on a uniform density approximation. To reduce the computation, non-bonded forces were
calculated using an r-RESPA integrator 47 where the short-range forces were updated
every step and the long-range forces updated every three steps. The trajectories were
saved at 40.0 ps intervals for analysis.
To check the convergence of MD simulations, the protein Cα and ligand RMSD
plots were investigated for each trajectory. The relatively flat plots within last 200 ns
indicates that the complex systems have reached a steady state.
Desmond SID tool was used to analyze the behavior and interaction of proteins
and ligands during the course of simulation including RMSD; protein-ligand contacts
including H-bonds, hydrophobic, ionic, and water-bridge contacts; secondary structure
changes and Root Mean Square Fluctuation (RMSF) measures.
2.2.5 Trajectory Clustering Analysis
Desmond trajectory clustering tool 48 was used to group complex structures from
the last 100 ns simulation of each complex system. Backbone RMSD matrix was used as
structural similarity metric, the hierarchical clustering with average linkage 48 was
selected as the clustering method. The merging distance cutoff was set to be 2Å. The
centroid structure (i.e. the structure having the largest number of neighbors in the
structural family) was used to represent the structural family. The centroid structures of
populated structural families (>2% of total structure population) are shown in Figures
A5-A6 of the supporting material.
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2.2.6 RMSD of Protein Structure Analysis
We analyzed the RMSD of the whole protein, transmembrane domain (TMD),
and TM6 for each trajectory in reference to both the solved inactive crystal structure of
the DOR (PDB ID: 4N6H) and the solved active crystal structure of the DOR (PDB ID:
6PT3) to aid in differentiating the protein in the active or inactive state. Alignment of the
whole protein is based on the backbone residues of the protein excluding backbone
residues of TM6 (4N6H: 36-248, 288-321, 6PT3: 45-248, 288-321), and alignment of the
7TMs is based on backbone residues of TM1-5&7 (4N6H: 39-77, 82-111, 117-152, 161187, 206-243, 293-321; 6PT3: 45-77, 82-111, 117-152, 161-187, 206-243, 293-321), both
of which exclude oxygen. RMSD calculations are of the backbone residues of the whole
protein (4N6H: 36-321, 6PT3: 45-321), 7TMs (4N6H: 39-77, 82-111, 117-152, 161-187,
206-243, 250-286, 293-321; 6PT3: 45-77, 82-111, 117-152, 161-187, 206-243, 250-286,
293-321), and TM6 (250-286). Maestro’s Simulation Event Analysis was used to
calculate the RMSD of the MD simulation. VMD RMSD Calculator49 was used to
calculate the RMSD of the portions of each representative structure of abundant clusters
from each trajectory.
2.2.7 Analysis of Microswitches and Pairwise Residue Distance
We analyzed three important microswitches50 , i.e., transmission (CWXP),
tyrosine toggle (NPXXY) and ionic lock (DRY) which are used to differentiate between
active and inactive states of class A GPCR. Another lock known as 3-7 lock50 was also
investigated.
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Framewise center of mass distances were calculated for 23 pairs of residues. Out
of 23 pairs of residues, 20 were previously used by Zhou et al.,29 to define the activation
of mechanism of class A GPCRs. For calculation of atomic and center of mass distances,
VMD49 was used.
2.2.8 Normal Mode Analysis
The individual trajectories from both systems were used in the Normal Mode
Wizard in VMD51 to generate a principal component analysis of the top 10 normal
modes.
2.3 Results
2.3.1 Sequence-Based Comparison of Human DOR With Other Class A GPCRs
Comparison of primary sequence of human DOR with 61 class A GPCRs
revealed that DOR sequence was more conserved at subfamily level than the family level.
Residues belonging to molecular switches such as CPXY, NPXXY and D/ERY motifs
showed high level of conservation at both family and subfamily levels. DOR showed
more than 50% identity with kappa (κ) and mu (µ) opioid receptors.
2.3.2 Homology Model of Human DOR Without Fusion Protein
Homology models of the DOR for the generation of ADL5859 and naltrindole
bound complexes were obtained based on experimentally resolved crystal structure of the
human DOR with naltrindole (PDB ID: 4N6H) as described in the methods section. In
the homology model of the DOR, mutation P37S present in the crystal structure of DOR
was corrected. A cartoon representation is shown in Figure A2 from top and side
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viewpoints. This homology model is a valid starting structure for molecular docking and
simulations to inspect the activation mechanism.
2.3.3 Docked Conformation of ADL5859 Shows Similarity With the Co-Crystallized
Conformation of DPI-287 and Subtle Difference With Naltrindole
The docking protocol was validated by docking the co-crystallized naltrindole
back into the crystal structure of DOR (Figure 2). The result had an almost identical
overlap which suggests a satisfactory docking method. ADL5859 was docked into the
inactive receptor, resulting in a similar binding pose as the crystal agonist. Docked
conformation of ADL5859 showed interaction with salt bridge with D128 and non-polar
interactions with M132, W274, V281, L300 and Y308.
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Figure 2
Comparison Between the Docked Pose With the Crystal Pose of Ligands
Side View

Top View

Bottom View

Ligand

A
TM1
TM7

H8

TM6

TM2
TM5
TM3
TM4

B
TM1
TM7
H8

TM6

TM2
TM5
TM3
TM4

C
TM1
TM7
H8

TM6

TM2
TM5
TM3
TM4

Note. A: Comparison between final docked pose of ADL5859 (dark blue) with the crystal
pose of Naltrindole (red) in the inactive crystal complex structure (cyan) (PDB ID:
4N6H) B: Comparison of final docked pose of agonist ADL5859 with the crystal pose of
DPI-287 (orange) in the active crystal complex structure (tan) (PDB ID: 6PT3). C:
Comparison of antagonist Naltrindole (light blue) with the crystal pose of Naltrindole
(red) in the inactive crystal complex structure (cyan) (PDB ID: 4N6H) (C). Intracellular
and extracellular loops were removed in the top view for clarity.

23

2.3.4 MD Simulations of Human DOR With ADL5859 and Naltrindole Assume Steady
State
The complexes from Glide XP docking were used as the input structures to
perform six independent 1 µs molecular dynamic simulation for ADL5859-DOR
complex and three 1 µs molecular dynamic simulation for naltrindole-DOR complex.
The RMSD values of ADL5859 and naltrindole shows the flexibility of the ligand
interaction with the DOR. The movement of the ligand and the receptor during the
simulation was analyzed using the RMSD (Figure 3 and Figure A3 and A4). In the
RMSD plots for systems, the protein and ligand RMSD are approaching stable values
within the last 200 ns, indicating that the two complexes had been sufficiently
equilibrated and allowed for rigorous analysis. The protein RMSD for ADL5859 changes
~3Å which indicates that the protein is undergoing a large conformational change during
the simulation (Figure 3). The protein RMSD for naltrindole has a lower RMSD value
and remains more stable. The ligand RMSD for ADL5859 shows multiple fluctuations
around 200-400 ns during the simulation (Figure 3). Naltrindole RMSD has a large
fluctuation around 200 ns and again between 800-950 ns.
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Figure 3
Protein (Blue) and Ligand (Red) RMSD

A

B

Note: Averaged over the six independent trajectories for agonist ADL5859-DOR system
(A) and three independent trajectories for antagonist Naltrindole-DOR system (B).
Alignment is based on the Cα atoms of the protein and the RMSD calculation with
reference to the first frame. Ligand RMSD calculated the ligand heavy atoms after the
complex is first aligned on the protein backbone of the reference.
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2.3.5 ADL5859-DOR System Shows Adopting Toward the Crystal Active Conformation
While Naltrindole-DOR System Maintains Inactive Conformation
To determine whether our agonist MD complex can adopt toward the active
conformation and move away from the inactive conformation, the RMSD of the receptor
against the active and inactive crystal structures was calculated throughout the whole
trajectory. The RMSD of the whole protein, TMD, and TM6 of the receptor was
calculated to home in on which portion of the protein has the most conformational
change, presumably leading to activation. The RMSD of the same regions for the
antagonist naltrindole system was calculated as well to determine if the MD complex will
maintain the inactive conformation to serve as a control. For this to be clear, our
complexes were aligned against the inactive and active crystal structures (4N6H & 6PT3)
using the backbone residues of the TMD excluding TM6. The reason for this exclusion is
because TM6 appears to have the most dynamics while the other transmembranes are
more rigid. Aligning the rigid parts of the receptor will better show the change in
conformation of the flexible part. Examining the whole protein of the individual agonist
RMSD plots (Figure A5) revealed that trajectories 1, 3, 5, and 6 behave similarly as they
clearly show a general trend where they increase in RMSD when against the inactive
crystal structure and decrease in RMSD when against the active crystal structure. This
trend becomes more pronounced when looking at the RMSD of the TMD for these
trajectories and even more so for the RMSD of TM6. Using trajectory 1 as an example,
the RMSD value of the TMD at the beginning of the trajectory against the inactive crystal
structure is 1.9Å and ends at 2.4Å; and when against the active crystal structure, the
RMSD value begins at 3.0Å and ends at 2.4Å. With this same process for TM6 in
trajectory 1, the RMSD values when it first begins against the inactive crystal structure is
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3.3Å and ends with an RMSD value of 4.2Å; and when against the active crystal
structure, it begins with an RMSD value of 5.7Å and ends with an RMSD value of 4.0Å.
This indicates the major part contributing to the protein folding is the movement in TM6.
Trajectory 4 of the agonist system shows the same trend within the first 800 ns as
trajectories 1, 3, 5, and 6 but after 800 ns, it reverses the process with an increasing trend
against the active crystal structure and decreasing trend against the inactive crystal
structure. Trajectory 2 of the agonist system differs from the others in which it only
maintains the same RMSD trend as the other trajectories during the first 200 ns but still
not as clear. After 200 ns, especially for the RMSD of TM6, it loses the general trend and
levels out. To clarify what this means, using the RMSD of TM6 in trajectory 2, when
against the inactive conformation at 200 ns has an RMSD value of 2.3Å and ends with an
RMSD value of 2.4Å; and when it is against the active conformation at 200 ns has an
RMSD value of 4.3Å and ends with an RMSD value of 4.5Å. In the case of the RMSD
for the antagonist naltrindole system (Figure A6), all three trajectories displayed the same
pattern for each protein region in which there was no change in RMSD when against
either crystal structures. From these results we can speculate that if the system adopts
toward the active conformation, it should decrease in RMSD against the active crystal,
favoring smaller RMSD values, and increase in RMSD against the inactive crystal,
favoring larger RMSD values. If there is no protein folding within the system, then the
RMSD should not change which would be validated by flat RMSD plots. Because the
majority of the agonist trajectories shared a general trend in RMSD and all antagonist
trajectories shared a general trend in RMSD, the individual trajectories were averaged to
simplify the results (Figure 4). After averaging the trajectories for both systems, a
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noticeable feature in the RMSD became more apparent. For both simulation systems
(agonist & antagonist), there is a gap between the starting values of the RMSD when
against the reference structures, with the inactive reference structure at much lower
values than when against the active crystal structure. Our simulation systems began using
the inactive conformation which correlates with this feature that our systems are more
similar to the inactive crystal structure at the beginning of the trajectory, depicted by
lower RMSD values. This gap gets larger as the protein regions get more specific (whole
protein → TMD → TM6), indicating the difference between the conformation of the
reference structures increases as the RMSD gets more specific. The averaged agonist
trajectories show to have maintained the same clear trend in RMSD as its individual
trajectories throughout the protein regions, with the gap diminishing between the
reference structures throughout the trajectory, and the most prominent trend occurring in
TM6.
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Figure 4
Receptor RMSDs of Varied Parts From Agonist and Antagonist Simulation Systems
Against the Two Solved Crystal Receptor Structures
Agonist ADL5859 system

Antagonist Naltrindole system

A

B

C

Note: A: RMSD of protein = backbone residues 36-321 (4N6H), 45-321 (6PT3). B:
RMSD of 7TMs = backbone residues of TM1-7. C: RMSD of TM6 = backbone residues
250-286. (PDB ID: 6PT3 Active state DOR in complex w/ agonist DPI-287) (PDB ID:
4N6H Inactive state DOR in complex w/ antagonist Naltrindole).
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The RMSD of the averaged agonist system of the whole protein against the active crystal
begins with an RMSD of 3.5Å and ends with a decreasing RMSD of 3.4Å showing a
difference of .1Å. When against the inactive crystal, the whole protein begins with an
RMSD of 2.4Å and ends with an increasing RMSD of 3.4Å, showing a difference of 1Å.
The TMD displays the trend in RMSD more clearly with the average agonist trajectories
against the active crystal beginning at an RMSD of 2.9Å and ending with an RMSD of
2.7Å, showing a decreasing difference of 0.2Å. When against the inactive crystal, the
TMD begins with an RMSD of 1.6Å and ends with an RMSD of 2.6Å, showing an
increasing difference of 1Å. The greatest difference in RMSD lies in TM6 beginning with
an RMSD of 5.6Å against the active crystal and ending with a decreasing RMSD of 4.4Å,
indicating a 1.2Å difference. When against the inactive crystal structure, TM6 of the
averaged agonist trajectories begins with an RMSD of 2.6Å and ends with an increasing
RMSD of 3.6Å, showing a 1Å difference. The trend in RMSD of the whole protein and
the TMD of the agonist system was not as drastic, indicating TM6 shows the most change
in conformation. When viewing the RMSD of the averaged antagonist trajectories, they
have still maintained the trend of no change in RMSD with relatively flat plots. The gap
between the reference structures is maintained throughout the whole trajectory for each
protein region, indicating the antagonist system is more similar to the inactive crystal
structure and less similar to the conformation of the active crystal structure. When against
the active crystal structure, the averaged antagonist system of the whole protein begins
with an RMSD of 3.1Å and ends with an RMSD of 3.2Å, showing a .1Å difference.
When against the inactive crystal structure, the RMSD of the whole protein begins at
3.3Å and ends with an RMSD of 3.3Å, indicating no change from the inactive reference
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structure. The RMSD of the TMD when against the active crystal structure begins at 2.9Å
and ends with an RMSD of 3.0Å, showing an increase of .1Å. When against the inactive
crystal structure, the TMD starts with an RMSD of 2.4Å and ends with an RMSD of
2.4Å, again showing the antagonist system has not folded away from the inactive
conformation. The RMSD of TM6 of the averaged antagonist system when against the
active crystal structure begins at 5.2Å and ends at an RMSD of 5.3Å, showing a 0.1Å
increase. When against the inactive crystal structure, TM6 begins with an RMSD of 2.4Å
and ends with an RMSD of 2.5Å, showing another 0.1Å increase. This data alludes to
our agonist system folding towards the active conformation as the gap between the
reference structures dies out with a decreasing trend against the active crystal structure
and an increasing trend against the inactive crystal structure. Lower RMSD values
against the active crystal structure indicate greater similarity with the active conformation
and in this same respect, higher values against the inactive crystal structure indicate the
difference from the inactive conformation. This trend was the most prominent for the
RMSD of TM6 of the agonist system, which movement of is associated with activation in
GPCRs. In the case of the antagonist system, the RMSD of the different protein regions
showed either a change of 0.1Å or no change at all while also maintaining the gap
between reference structures, which would imply that the system has not folded away
from the inactive conformation. From the backbone RMSD plots, it is clear the activation
related conformational changes are unique to the agonist-ADL5859 bound DOR.
2.3.6 ADL5859-DOR System Has Multiple Clusters Folding Toward the Active State
The clustering analysis was done after the MD simulation to identify the
populated conformation for each trajectory. Based on the clustering algorithm, each
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cluster conformation contains a percentage of abundance in which a cutoff of 1% was
used. The clustering results are clearly tabulated in Table A1. There was a total of 15
abundant clusters from the six agonist trajectories with each trajectory containing at least
two abundant conformations, with the exception of trajectory 2. For the three antagonist
trajectories, there were three abundant clusters, one for each independent trajectory. The
clustering result for both systems corresponds with the thought that the agonist system is
believed to be folding towards the active state which would produce more than one
conformation; and in this same regard, the antagonist system should not have any folding,
which would result in one conformation.
To acquire a deeper insight into the conformation of the MD structures, the
RMSD of the whole protein, TMD, and TM6 of each abundant cluster against the
inactive and active crystal structures was calculated as described in the Methods (Table
A1 and Figure A7-A8). To consider an abundant cluster as folded toward the active state,
when comparing the RMSD values of the protein regions against the different crystal
structures, especially in the case of TM6, they should differ roughly by at least 1 Å, with
lower values when against the active crystal structure, indicating greater similarity. The
RMSD values of the abundant clusters from the antagonist system against both crystal
structures were also taken into consideration when determining the criteria for folding
toward the active state as this system should remain in the inactive state. Each cluster of
the antagonist system had an RMSD ranging from 3.1-3.4Å for the whole protein when
against the active crystal structure and 3.1-3.3Å when against the inactive crystal
structure. When looking at the TMD, the antagonist abundant clusters had an RMSD
ranging from 2.8-3.0Å when against the active crystal structure and 2.7-2.8Å when
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against the inactive crystal structure. The last protein region calculated for the RMSD of
the naltrindole complexes, TM6, had RMSD values ranging from 4.9-5.5Å against the
active crystal structure and 1.8-2.9Å against the inactive crystal structure. After
calculating the RMSD of each of the agonist clusters against the crystal structures, there
were three trajectories (trj1, trj4, trj6) and four clusters (trj1 cluster 1&3, trj4 cluster 5,
trj6 cluster 1) that can be considered in the active state. The most abundant cluster
(cluster 1) from trajectory 1 in the agonist system is the most favorable from this system
and is used as the representative structure (Figure 5). The interactions of agonist
ADL5859 with the DOR from the first trajectory were examined, along with the crystal
antagonist naltrindole in the crystal inactive state DOR, and the crystal agonist DPI-287
in the crystal active state DOR. With this, ADL5859 directly interacted with polar
histidine 278 of the DOR during the simulation, which is consistent with the interactions
of crystal agonist DPI-287 and the DOR. Both agonists also have exposure to solvent on
the same CH3 of their structures. The clusters from the naltrindole system show good
agreement with the inactive crystal structure and were validated by the RMSD values
with the abundant cluster from the first trajectory used as the representative structure
(Table A1, Figure A7 and Figure A8). Naltrindole directly interacted with negatively
charged aspartic acid 128 of the DOR during the simulation which is consistent with the
interactions of crystal antagonist naltrindole and the DOR. This indicates the
conformational changes occurring to the receptor are unique to the agonist ADL5859DOR system.
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Figure 5
Most Abundant Agonist Cluster of the First Trajectory Compared to Solved Crystal
Structures and Structural RMSD Calculations
MD Structure

MD/Crystal Inactive Structure

MD/Crystal Active Structure

Protein: 3.4 Å

Protein: 2.5 Å

7TMs: 2.8 Å

7TMs: 2.2 Å

TM6: 4.1 Å

TM6: 3.4 Å

TM1
TM5
H8

TM6

TM1

TM1

TM7
TM6

H8

TM1
TM7

TM7
TM6

H8

H8
TM6
TM2

TM2

TM2
TM5

TM5

TM3

TM3

TM5

TM3
TM4

TM4
TM4
TM6

TM6
TM6

H8

H8

H8
TM5
TM5

TM5

TM3

TM3

TM3
TM4

TM4

TM4

Note. MD DOR-agonist-ADL5859 structure (purple&blue) of the most abundant cluster
(52%) of the first trajectory, its comparison to the solved crystal structures (Inactive PDB
ID: 4N6H, cyan&red) (Active PDB ID: 6PT3, tan&yellow) in the side, top, and bottom
views respectively. RMSD of the protein, 7TMs, and TM6 of the MD structure against
crystal structures is listed. Alignment is using backbone residues of TM1-5&7, excluding
oxygen. Ligand view of MD-DOR-ADL5859, crystal antagonist Naltrindole in inactive
DOR, and crystal agonist DPI-287 in active DOR.
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While the RMSD of the superimposed agonist structures indicated four clusters folding
toward the active state, there were other abundant clusters from the agonist-ADL5859
system that are thought to contain intermediate conformations of the protein folding
toward the active state (Figure A7). These other noteworthy structures are cluster 1 and
cluster 2 from trajectory 3 with a percentage of abundance of 90 and 11 respectively;
trajectory 4 cluster 1, cluster 3, and cluster 4 with percentages of abundance of 43, 20,
and 5 respectively; and cluster 1 from trajectory 5 with a percentage of abundance of 56.
Even though these structures did not have as favorable of RMSD values as the others that
were identified, they are speculated to be intermediate conformations in the activationrelated folding process, as they also still display agreement with the active crystal
structure and contain great differences from the inactive crystal structure. The differences
from the inactive crystal structure mentioned mainly lie in TM5, ICL3, and TM6 while
similarities to the active crystal structure mainly lie in TM1, TM5, and TM6. These
clusters, along with the ones identified from the RMSD as folding toward the active state,
are consistent with the results from the backbone RMSD plots (Figure A5-A6), in which
the trajectories these cluster conformations were generated from (trj1, trj3, trj4, trj5, trj6)
displayed the general trend implying protein folding toward the active conformation
throughout the simulation. This adds further support of the agonist-ADL5859 system
folding toward the active state.
2.3.7 Secondary Structure Analysis Shows Maintained Helices but With Subtle
Differences Between the Two Complexes
Secondary structure elements (SSE) plots illustrate where the major differences
occur in the transmembrane sections for comparisons to be made between the agonist and
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antagonist (Figure A9). Some of the noteworthy features include: A) Additional kink in
ADL5859 in TM6. B) Additional kinks in naltrindole in TM2 and TM7.
2.3.8 Key Interactions of ADL5859 and Naltrindole With Human DOR
The Desmond Simulation Interaction Diagram was used, as described in the
methods section, to analyze and compare the residues involved in both naltrindole and
ADL5859 binding to the receptor (Figure 6). The key interacting residues that interacted
with each ligand of the combined trajectories for more than 5% of the simulation are
tabulated for clarity in Table S4. Key interacting residues of the individual trajectories for
the agonist and antagonist systems that lasted more than 20% of the MD simulation can
be found in Figure A10 and Figure A11, respectively. Interacting residues during the
simulation in histogram format of the individual agonist and antagonist trajectories can be
found in Figure A12 and Figure A13, respectively. Using Figure 6 it can be understood
that ADL5859 interacted with a greater number of residues from the receptor with a total
of 47 interacting residues that mainly occur in TM2, TM3, TM5, TM6, and TM7.
Naltrindole had a total of 30 interacting residues in which 26 of them were conserved in
ADL5859. In TM6, there were 6 conserved interacting residues between the two systems.
Naltrindole, however, interacted with residue I282 which differed from ADL5859 that
interacted with residues F270 and W285. The major differences lie in TM7 where
ADL5859 had 10 interacting residues: V297; L300; H301; C303; I304; G307; Y308;
N310; S311; N314 whereas naltrindole had only 6: L300; I304; G307; Y308; N310; and
S311. The 2D interaction diagram indicates that π-π stacking is crucial for the binding of
both ligands (Figure 6).
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Figure 6
Protein-Ligand 2D Interaction Diagram

ADL5859

Naltrindole

Note: Interactions lasting more than 20% of the molecular dynamics simulation from the
combined agonist (left) and antagonist (right) trajectories are shown in the 2D interaction
diagrams.

2.3.9 DOR Shows Flexibility When Bound to ADL5859 Than Naltrindole
The receptor RMSF (Table 1, Figure 7 and Figure A14-A15) shows higher RMSF
values in areas of high flexibility such as the intra- and extracellular loops, as well as the
N- and C- terminals. In contrast, the helices, or rigid areas of the receptor, show lower
RMSF values. When the DOR was bound to ADL5859, the receptor RMSF values were
higher than when bound to naltrindole. ADL5859 has higher ligand RMSF values in
comparison to naltrindole (Figure 7). In Figure 7, naltrindole has lower RMSF values at
almost every atom. This is consistent with what was expected from the structures of the
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two ligands – for naltrindole contains one more six membered ring than ADL5859, as
well as two five membered rings and one three membered ring, making naltrindole a
more rigid ligand compared to ADL5859. These differences indicate that the DOR
exhibited greater flexibility when interacting with an agonist (ADL5859) than with an
antagonist (naltrindole). This is likely because the receptor was undergoing activation
when in complex with ADL5859. Receptor RMSF data of the individual trajectories can
be found in Figure A14-A15 of the appendix and individual ligand RMSF data can be
found in Figure A16-A17 of the appendix.

Table 1
The Combined Mean RMSF Values of the Ligand Bound Complex From N-Terminal to
C-Terminal
RMSF (Å)
ADL5859
Naltrindole

N-term
8.1
2.5

ICL
2.2
1.9

ECL
2.0
1.5
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Helices
1.27
0.9

Ligand
0.5
0.3

Figure 7
RMSF Comparison

Note. The root mean square fluctuation of the Cα atom for residues in the delta opioid
receptor in complex with agonist ADL5859 (trj1) (blue) and antagonist Naltrindole (trj1)
(red) is shown with the DOR architecture above for reference (top). Ligand RMSF values
for ADL5859 (blue) and Naltrindole (red) (bottom). The root mean square fluctuation of
the atoms in both ligands as indicated in their numbering.
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2.3.10 Distance of ADL5859 With Side Chain of D95 Decreases While Naltrindole
Shows No Change
Residue D952.50 plays an important role in DOR activation signaling. Mutagenesis
studies have shown that G protein signaling is affected in GPCRs when D2.50 is replaced
with a neutral amino acid.52 Measuring the distance of the positively charged nitrogen
atom of agonist ADL5859 and antagonist naltrindole with D95 of the protein shows a
clear difference between the two systems (Figure 8). In the agonist ADL5859 system, the
distance decreases about 4Å inferring a salt bridge formed with the ligand. The antagonist
system shows no change in distance, further supporting the DOR in complex with the
antagonist naltrindole maintained the inactive conformation.

Figure 8
Average Distance Timeline Between Positively Charged Nitrogen Atom of Ligand and
Side Chain of D95

Note: For ADL5959-DOR system, average values of traj1 and traj6 and for naltrindoleDOR system average values of all three trajectories over 1µs are shown.
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2.3.11 Role of Molecular Switches in the Activation of DOR by ADL5859
Class A GPCRs share a set of conserved motifs which are known as molecular
switches. Activation of the class A GPCR can be characterized by the conformational
changes in one or more molecular switches. Molecular switches were evaluated
throughout the entire trajectories of ADL5859-DOR and naltrindole-DOR systems. For
the DOR, three such motifs are considered to be critical in regulating its activity:
Transmission Switch (CWXP) in TM6, Ionic Lock Switch (DRY) in TM3 and TM6, and
Tyrosine-Toggle Switch (NPXXY, X represents any amino acid) in TM7. Each abundant
cluster from the individual trajectories of both simulation systems was compared to the
solved crystal structure of the inactive DOR in complex with antagonist naltrindole (PDB
ID: 4N6H) to measure the switch distances. We have determined five abundant clusters
in the agonist system (trj1 cluster 1&3, trj3 cluster 2, trj4 cluster 5, trj6 cluster 1) to have
broken molecular switches, inferring activation, based on the transmission switch and
ionic lock switch as there was no significant change in the tyrosine toggle switch for any
of the clusters (Figure 9, Figure A18-A25). Trajectory 1 cluster 1 is the most favorable
from the agonist system as is used as the representative structure (Figure 9). The key
distances characterizing the switches for all trajectories of ADL5859 and naltrindole are
summarized in Table A2.
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Figure 9
Molecular Switches

Note: The crystal structure of Naltrindole and MD ADL5859 (trj 1 cluster 1) ligands in
complex with DOR (crystal Naltrindole/DOR: red/cyan; ADL5859/DOR: blue/purple).
B. Transmission Switch (CWXP) C. Tyrosine Toggle Switch (NPXXY) D. Ionic Lock
Switch (DRY). B-D: crystal Naltrindole/DOR: red/cyan; ADL5859/DOR: blue/purple.

The transmission switch is the most observable switch out of the three that when
in the active state, a large outward “swing” occurs in TM6. Our molecular switch analysis
shows this same “swing” in our agonist ADL5859 system ranging from 9.2Å-13.9Å. The
naltrindole system displays a motion of 3.8Å and 3.0Å in TM6 indicating it lacks any
significant outward motion of TM6. One of the aromatic rings of ADL5859 showed
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interaction with the side chain of W274, a highly conserved residue in the transmission
switch. This is consistent with the active crystal structures of the DOR exhibiting slight
rotameric change at the level of W274. Naltrindole also interacts with W274 but
interaction is weak compared to ADL5859. The salt bridge between D3.49 and R3.50
residues in the DRY motif is already disrupted in the inactive DOR with distances of
>3.5Å and is missing an acidic residue in position 6.30, which is only conserved in about
30% of GPCRs. To compensate for this, we measured the hydrogen bonding between
residues R1463.50 and T2606.34, for this interaction is thought to stabilize receptors in the
inactive state and may be important for regulating receptor signaling.53 When measuring
the distance of the agonist-ADL5859 system, the hydrogen bonding between residues
R1463.50 and T2606.34 was disrupted in trj1 cluster 1, trj3 cluster 2, trj4 cluster 5, and trj6
cluster 1 with distances ranging from 4.2Å-9.3Å, implying the inactive state of the
receptor was destabilized. The distances for the ionic lock switch in the antagonistnaltrindole system ranged from 3.7-4.4Å, indicating it was only broken in one trajectory
(trj 2).
2.3.12 Center of Mass Distances Identify Activation Related Changes
The conserved motifs in molecular switches of Class A GPCRs were used as the
motivation to search for other potential motifs in examining the conformational changes
throughout the simulation systems (Table 2).
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Table 2
Residue Pairs for Center of Mass Distance Measurement
ID

Residue pair

Location

Nature of interaction

Reference

1

S249-S249

TM6

Self CA-CA distance

Present study

2

W274-W274

TM6

Self CA-CA distance

Present study

3

Y318-Y318

TM7

Self CA-CA distance

Present study

4

R146-T260

TM3-TM6

H-bond

1

5

I226

5.51

I136

3.40

6
7
8
9
10
11
12
13
14
15
16
17

T230
L139

3.47

L139

TM5-TM6

Hydrophobic/ van der Waals contact

TM3-TM6

Hydrophobic/ van der Waals contact

-V267

6.41

TM5-TM6

Van der Waals contact

-N314

7.49

TM3-TM7

Van der Waals contact

6.40

TM5-TM6

Hydrophobic/ van der Waals contact

7.53

TM3-TM7

Hydrophobic/ van der Waals contact

7.53

TM3-TM7

Hydrophobic/ van der Waals contact

3.50

TM3-TM3

Van der Waals contact

7.53

TM3-TM7

H-bond/Cation pi

-W274

5.55

Y233

5.58

3.43

-V266

-Y318

M142

3.46

M142

3.46

R146
V70

3.50

1.53

L237
L139

3.43

M142

19

R146

20

D145

21

V70

22

M236

23

R146

24

V265

25

R258

26

L139

TM1-TM7

Hydrophobic/ van der Waals contact

-V263

TM5-TM6

Hydrophobic/ van der Waals contact

-V267

6.41

TM3-TM6

Hydrophobic/ van der Waals contact

7.49

TM6-TM7

Hydrophobic/ van der Waals contact

6.37

TM3-TM6

Hydrophobic/Van der Waals contact

6.37

TM3-TM6

Hydrophobic/ van der Waals contact

3.50

TM3-TM3

Van der Waals contact/Salt bridge

TM1-TM7

Hydrophobic/ van der Waals contact

TM5-TM7

Hydrophobic/ van der Waals contact

3.53

TM3-TM3

Van der Waals contact

7.56

TM6-TM3

Van der Waals contact

Present study

8.48

TM6-TM8

Salt bridge

Present study

6.40

TM3-TM6

Van der Waals contact

Present study

3.50

-N314

-R146

-Y318

5.61

3.50

6.32

7.53

-A319

-A149

6.39

2.43

-V263

-V263

3.49

3.43

7.54

2

6.36

3.46

1.53

-R146

-Y318

6.40

18

-Y318

-A319

5.62

V266

6.44
6.48

-F270

-L321

-E323

-V266

7.54

6.36

27
TM2-TM6
Hydrophobic/ van der Waals contact
Present study
I88 -M262
1.
Claff, T.; Yu, J.; Blais, V.; Patel, N.; Martin, C.; Wu, L.; Han, G. W.; Holleran, B. J.; Van der Poorten, O.;
White, K. L.; Hanson, M. A.; Sarret, P.; Gendron, L.; Cherezov, V.; Katritch, V.; Ballet, S.; Liu, Z.-J.; Müller, C. E.;
Stevens, R. C., Elucidating the active δ-opioid receptor crystal structure with peptide and small-molecule agonists. Sci
Adv 2019, 5, eaax9115-eaax9115.
2.
Zhou, Q.; Yang, D.; Wu, M.; Guo, Y.; Guo, W.; Zhong, L.; Cai, X.; Dai, A.; Jang, W.; Shakhnovich, E. I.;
Liu, Z.-J.; Stevens, R. C.; Lambert, N. A.; Babu, M. M.; Wang, M.-W.; Zhao, S., Common activation mechanism of
class A GPCRs. eLife 2019, 8, e50279.
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From the literature, 18 pair-wise residues were identified that were analyzed in
this study, including several hydrophobic and van der Waals contacts, as well as
hydrogen bonding and salt bridges.29 In addition, four atomic mass distances were
measured from the molecular switch motifs: S249-S249 in TM6, W274-W274 in TM6,
Y318-Y318 in TM7, R146-T260 hydrogen bonding between TM3-TM6.28 When a
residue is a part of TM6, the distance between that and the other transmembrane helices,
particularly TM3 and TM7, should increase, breaking any interactions. Based on this,
four pair-wise residues involving TM6 that are also conserved in the subfamily (opioid
receptors) level were additionally measured: V265-L321 Van der Waals contact, R258E323 salt bridge, L139-V266 Van der Waals contact, I88-M262 hydrophobic and Van
der Waals contact. In total, we analyzed 27 distances, measuring the center of mass
between residues, to investigate the conformational changes over the whole trajectory for
the average of both simulation systems (Table 3). Through this, seven distance profiles
were identified that are associated with activation. A significant increase in the distance
of the center of mass is observed in the agonist system when one of the residues in a pair
is a part of TM6. The timelines for the distances involving residues in TM6 for both
systems are shown in Figure A26. In the agonist-ADL5859 system, trajectory 1 and 6
displayed similar distance profiles with a general increasing trend, and because of this,
were averaged together to simplify the distance timeline. The three antagonist-naltrindole
trajectories displayed similar distance profiles as well with a general slightly decreasing
trend, and therefore, were averaged together to simplify the distance timeline. The
greatest difference between the two simulation systems can be observed between residues
I882.43 and M2626.36 located at the intracellular portions of TM2 and TM6. Over the
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course of the simulation for the agonist system, this residue shows a large increase
throughout the ADL5859 timeline with a change of 4.1Å. The timeline of the naltrindole
system shows this residue to be gradually decreasing throughout the simulation with a
change of 0.2Å. This is consistent with the previously mentioned thought that the
distance between TM6 and other transmembrane helices should increase.

Table 3
Average Atomic and Center of Mass Distances
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2.3.13 Normal Mode Analysis Shows the Overall Motion of the Receptor
The normal mode analysis (Figure S27-S28) shows the top 10 low vibrational
modes identified from the principal component analysis, however modes 1-3 show the
most difference in motion. The overall motion of the receptor is significant, however, the
motion of TM6 is presumed to be a hallmark in determining the state of the receptor (i.e.
active, inactive) and therefore can be focused in on for clarity. Using our representative
structures from our two systems, our analysis identified the ADL5859 system having a
higher degree of fluctuation and a more distinct motion when compared to naltrindole. In
the top mode of the ADL5859 system, the ends of TM5, TM6, and ICL3 appear to be
moving outward, deeming the bottom of the receptor to be open, or otherwise, in the
active state. The motion in the naltrindole system of the same region can be observed as
moving back towards TM3 and TM4, still in a closed position. This analysis was also
performed on trajectory six of the ADL5859 system and the remaining two trajectories of
the naltrindole system. Trajectory six of the ADL5859 system had maintained similar
modes of motion from the first agonist trajectory-. The two trajectories from the
naltrindole system also maintained similar modes of motion from the first antagonist
trajectory.
2.4 Discussion
Computational studies have been utilized in studying the DOR even before crystal
structures became available, however, to our best knowledge, no known studies have
applied the use of MD simulations to study its activation mechanism started from an
inactive conformation. Molecular dynamic simulations is extremely powerful tool to
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probe deeper into the interactions and dynamics occurring in a protein system. Starting
from the inactive state of the DOR and sampling its active conformation in the presence
of a small molecule agonist offers an opportunity to explore the structural basis of DOR
activation. Using agonist ADL5859 adds to the novelty due to its lack of a crystal
structure and unknown interactions with the DOR. ADL5859 shares a pharmacophore
with the crystal agonist DPI-287 (Figure 1), implying their interactions with the DOR
will be similar, validating the use of this small molecule ligand for this study. The crystal
antagonist naltrindole was used as our second simulation system in order to determine if
the inactive conformation of the DOR when bound to an antagonist can be maintained in
MD simulations to serve as a negative control. Here we present the first study probing the
active conformation of the DOR started from an inactive conformation using MD
simulations.
After docking the ligands into the homology model, both agonist ADL5859 and
antagonist naltrindole resulted in docking conformations consistent with the crystal
ligand poses (Figure 2).28, 54 This validated our initial poses for the MD simulation of
both ligands. Following the simulation of both systems, the calculation of RMSD
throughout the simulation of different protein regions against both crystal structures
(4N6H, 6PT3) offered a deeper insight into the structural change response of the DOR
when bound to an agonist or antagonist (Figure 4). The gap between the crystal reference
structures in the RMSD plots indicated both simulation systems were more similar to the
inactive conformation at the start of the simulation, which is consistent with our starting
structures that were generated based on the inactive crystal structure (4N6H). Decreasing
in RMSD against the active crystal structure while increasing in RMSD against the
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inactive crystal structure would suggest that the system is adopting toward the active
conformation. Encouragingly, the agonist-ADL5859 system followed this RMSD trend
with the most apparent in TM6. This correlates with what is known about GPCRs, that
TM6 outward opening is a hallmark of the activation in class A GPCRs.50 The RMSDs in
the antagonist system only showed no change. This analysis supports our agonist system
folding toward the active conformation and our antagonist system maintaining the
inactive conformation.
The trajectory clustering analysis identified the populated conformations of the
individual trajectories throughout the simulation that helped to gain further insight into
the DOR complexes (Table A1, Figure 5, Figure A7-A8). Expecting the agonist bound
DOR to undergo conformation change, it can be understood that the majority of the
individual agonist trajectories contained more than one populated cluster conformation.
In contrast, the individual antagonist trajectories each generated only one populated
cluster conformation, as they were not expected to have changed from their initial
inactive conformation.
After calculating the RMSD of different portions of the receptor when
superimposed with the crystal structures, we were able to identify three independent
activating events of the ADL5859 system that supports the DOR folding toward the
active conformation, with the most notable hallmark as the RMSD of TM6. The first
event occurred in the first trajectory where cluster 1 (52%) and cluster 3 (17%) were
structurally similar to the active crystal complex with favorable RMSD values (Cluster 1
RMSD TM6 Inactive: 4.1Å Active: 3.4Å ˖ Cluster 3 RMSD TM6 Inactive: 3.3Å Active:
2.9Å). The second event happened in the fourth trajectory where cluster 5 (1%) showed
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agreement with the active crystal complex with favorable RMSD values (Cluster 5
RMSD TM6 Inactive: 5.8Å Active: 2.8Å). The third event was in the sixth trajectory’s
most abundant cluster (76%) that was structurally similar to the active crystal structure
with favorable RMSD values (Cluster 1 RMSD TM6 Inactive: 3.9Å Active: 3.2Å). The
percentage of abundance of each event indicates >70% folding into the active state with
the 1% of abundance from trajectory 4 cluster 5 as a partial folding event. The agonist
bound clusters shared similar interacting protein-ligand residues as the active crystal
structure as well. In the three individual naltrindole trajectories, each abundant cluster
showed structural agreement with the inactive crystal structure (4N6H) with lower
RMSD values against 4N6H and higher values against 6PT3, further inferring its
similarity to the inactive conformation. This is further validating that the activation
related changes are unique to our agonist bound complex.
Superimposing the abundant structures to the crystal structures and calculating the
RMSD of different protein regions also opened speculation to other populated clusters
from the individual agonist trajectories as intermediate conformations in the protein
folding toward the active state. Trajectory 3 clusters 1 (90%) and 2 (11%); trajectory 4
clusters 1 (43%), 3 (20%), and 4 (5%); and trajectory 5 cluster 1 (56%) show some to
great agreement to the active crystal structure, especially in regions TM5-6, while
showing disagreement to the inactive crystal structure in these same regions. These
speculated intermediate active state folding structures add further support that our
agonist-ADL5859 system has undergone protein folding toward the active state as the
trajectories from which the structures came (trj3, trj4, trj5), in addition to the respective
trajectories of the identified active folding structures from the clustering RMSD
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calculation (trj1, trj4, trj6), are consistent with the individual agonist trajectories
determined as adopting toward the active conformation from the RMSD time series of the
whole simulation (trj1, trj3, trj4, trj5, trj6) (Figure A5-A6). This analysis has not only
offered support to the previous RMSD analysis, but has also added more insight into the
speculated activation process towards the activated DOR.
Comparing the two representative structures from the MD complexes revealed a
clear conformational difference in the receptors in the transmembranes as well as the
intra- and extracellular loops and the ligand binding pose. These differences in the protein
structures are consistent with the differences between the active and inactive crystal
structures. The binding pose of ADL5859 is lower than that of naltrindole, which may be
a result of the great conformational change occurring that could be pulling the ligand
deeper into the binding pocket. The MD simulations were successful in producing
different conformations in the DOR when bound to an agonist and antagonist. Our
simulation data supports the conformation selection mechanism for DOR activation.
The RMSF of the receptor (Figure 7 and Figure A14-A15) when bound to
agonist-ADL5859 indicated the complex had greater flexibility in the loops and terminals
when compared to the antagonist-naltrindole system which is consistent with not only the
pharmacological actions of the two ligands (agonist/antagonist), but also our hypothesis
that our agonist system adopted toward the active conformation. The ligand RMSF also
supports our hypothesis due to ADL5859 itself showing greater flexibility than
naltrindole. This is consistent with what is known, that an antagonist (naltrindole)
typically binds tighter to the receptor than an agonist (ADL5859). Naltrindole is also a
more rigid ligand compared to ADL5859, with more aromatic rings and less rotatable
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bonds, which tells enough in itself about the predicted flexibility of the ligands that was
produced in the ligand RMSF. The RMSF analysis is another indication supporting that
our agonist system underwent a conformational change.
Residue D952.50 is believed to be an important residue in the agonist-induced
cyclic adenosine monophosphate (cAMP) response that occurs in activated GPCRs.52 In
timeline plots, we see that in traj1 and traj6 decrease in the distance between ADL5859
and D95 correlates with DOR activation (Figure 8). In contrast, the distance between D95
and naltrindole has no change throughout the simulation, inferring that the helices have
not shifted, remaining in the inactive state.
Molecular switches are hallmarks in the classification of the activation state of
class A GPCRs.50 Previous studies have identified the lack of a salt bridge in inactive
opioid receptors which have a hydrophobic Leu6.30 in place of the usual acidic Glu6.30.54 It
was later realized hydrogen bonding between R1463.50 and T2606.34 residues may
stabilize the receptor in the inactive state similar to the salt bridge in the Ionic Lock
Switch.53 This interaction was analyzed as the Ionic Lock Switch along with the usual
Transmission and Tyrosine Toggle Switches. This hydrogen bonding was broken in
multiple trajectories with a distances of 4.2-9.3Å. A very recent study by Claff and
coworkers reported on the distance of the transmission switch on a mutant active state
DOR with a large outward movement on helix 6 with a distance of approximately 9.4 to
11.2Å28, which is consistent with our data that showed distances of 9.2-13.9Å. The
sidechain of W274 of the transmission switch also showed slight rotameric change,
indicating the receptor is in the active state. Any slight change in the orientation of side
chain of W274 can have direct effect on the residues of TM6 and other regions of DOR.
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This same study as previously mentioned also reported an inward shift of helix 7 at a
distance of 3.9Å, however, they speculate this greater shift may be attributed to the three
mutations they made in the sodium-binding pocket (N902.45S, D952.50G, N1313.35S).28 In
contrast, this shift was not observed in the trajectories of the agonist-ADL5859 bound
DOR. Tyrosine-toggle switch did not show significant change in ADL5859-DOR
complex. As for the Naltrindole complex, the three molecular switches remain intact,
which obstruct the outward movement of TM6 thus, blocking G protein signaling.
In addition, we have used multiple atomic and center of mass distances to
characterize the conformation differences between the active and inactive states of the
DOR. These differences could contribute the activation. Indeed, the seven residue pairs
were identified that are associated with activation.
The normal mode analysis (Figure A27-A28) shows the top 10 low vibrational
modes identified from the principal component analysis. Previous knowledge tells us that
the motion and conformation of transmembrane six is relative to the state of the receptor
(i.e. active, inactive). While the overall motion is significant, this area can be focused in
on for clarity. We conducted this analysis on trajectory 1 and 6 from our agonist system
and all three antagonist trajectories. Our analysis identified the ADL5859 system having
a higher degree of fluctuation and a more distinct motion when compared to naltrindole.
Altogether, the two agonist trajectories had seven conserved vibrational modes in which
they had similar motion (mode 1, 2, 3, 4, 7, 8, 9). The conserved vibrational modes where
motion was favored between the two trajectories were modes 1, 2, 4, and 8 where the
ends of TM5 and TM6 swing outward, opening the intracellular portion of the receptor
for G protein signaling that is crucial in GPCR activation. The motion of the naltrindole
53

system in the majority of the modes for all three trajectories of the same region can be
observed as moving back towards TM3 and TM4 or downward, still in a closed inactive
position. This further provided another level of insight into the essential dynamics of
these complexes in the lowest vibrational states. We can conclude from the normal mode
analysis that the overall dynamics of the two complexes are distinct from one another,
which further supports that the motion differences of these complexes are due to their
dynamic interactions as well as their pharmacological actions. Our analyses including
RMSD, RMSF, molecular switches, measuring the center of mass, and normal mode
analysis help to explain the activity differences on the receptor that cannot be explained
from the crystal antagonist alone.
The proposed activation pathway of the receptor started from the allosteric signal
from the agonist ligand to the intracellular domain that interact with the effector Gprotein has been summarized in Figure 10. When the agonist is bound to the DOR, it
forms strong interactions with W274 and D95 in layer 1-2, further leads to break
important interaction pairs from layer2 by layer4 such as V267-L139, V263-M142 and
others, and finally causing an outward shift of the intracellular domain of TM6. This is
consistent with what is known about class A GPCRs that the intracellular portion of this
helices should move outward when activating to allow for G-protein signaling.50 In this
same respect, TM3 shifts away from TM6, breaking any hydrogen bonding that stabilizes
the inactive conformation. While this occurs, TM7 also moves away from both TM3 and
TM6. During all of this movement, the extracellular portion of TM1 folds away from the
ligand and the binding pocket while TM2 shifts closer to the ligand. The key residues in
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the activation pathway identified from this study provides a short list for future
experimental mutagenesis study.

Figure 10
DOR Activation Pathway

Note. Binding of agonist to DOR led to flow of allosteric signal from layer 1 (containing
agonist binding residues) to different layers of human DOR.
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Chapter 3
To Probe Activation Mechanism of Agonist DPI-287 to Delta Opioid Receptor and
Novel Agonists to Using Ensemble-Based Virtual Screening With Molecular
Dynamics Simulations
3.1 Introduction
3.1.1 The Opioid Epidemic
While pharmaceuticals have made great strides over the years in many areas, the
field of pain management is still lacking. There are great medications that target pain and
are effective, however, there has been a rise in the use of opioids over the years that has
led to the opioid epidemic that Northern America and other parts of the world are in. The
use of opioids (legally and illegally) has risen between 10-14 times in the last 20 years,
with more than 42,000 deaths in 2016 in the USA occurring from opioid overdoses
alone.55, 56 Most prescribed opioids target the Mu Opioid receptor (MOR) which are
located in the reward areas of the brain.55, 57, 58 When opioid agonists bind to and activate
these receptors, it causes euphoria which can lead to addiction after repeated use. When
people have long-term use of opioids, they can build up a tolerance, meaning they need
higher doses to feel the same effect, and/or physical dependence, inferring the need for
opioid use to continue normalcy. If the user is leading down this track, it can cause
decreased gastrointestinal motility, anorexia, urinary retention, and finally, respiratory
depression leading to an opioid overdose. When a user stops taking opioids after
addiction and physical dependence has taken place, it leads to withdrawal symptoms such
as bone pain with muscle aches, changes in body temperature, hyperalgesia, insomnia,
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stomach cramps, nausea, and many dysphoric effects.56 Physical dependency along with
the known unattractive symptoms of withdrawal are major reasons people do not stop
taking opioids. The need for better pain management without addictive properties is
pressing.
3.1.2 DOR Target Potential
The DOR has shown to have potential in not only pain management, but also in
psychiatric and neurological disorders without the potential for dependence or respiratory
depression (Table 4).59-66 This makes the DOR an attractive target to further study to
potentially help alleviate the opioid epidemic in the world.

Table 4
Comparison Between MOR and DOR
Receptor
Type
Mu

Delta

Therapeutic
Function & Side
Effects
Pain relief
Euphoric effect –
Addiction, physical
dependence,
respiratory depression
Chronic pain relief

anti-depression
ischemic
preconditioning
Convulsions

Model Type

Reference

Humans

(Shipton, et al. 2018),
(Pergolizzi Jr, et al. 2020),
(Volkow, et al. 2017),
(Centers for Disease, et al.
2016)
(Holdridge, et al. 2007)
(Nadal, et al. 2006)
(Gavériaux-Ruff, et al.
2008)
(Filliol, et al. 2000)
(Broom, et al. 2002)
(Tian, et al. 2013)
(Min, et al. 2018)

Spinal administration rat,
Gene knockout mice

Gene knockout mice,
Forced swim assay rats
Ischemia reperfusion
injury rats, post-ischemic
mice
Systemic administration
mice, rats,
electroencephalographic
rhesus monkeys
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(Comer, et al. 1993)
(Jutkiewicz, et al. 2005)
(Danielsson, et al. 2006)

3.1.3 Previous Studies On the DOR
However, multiple studies have reported on convulsions in various animal models
with the use of DOR agonists. After systemic administration of a DOR agonist, mice
displayed convulsive effects.67 Using rats, tolerance rapidly developed to convulsive and
locomotor-stimulating effects of a selective DOR agonist but did not display tolerance to
the antidepressant-like effects.68 When using rhesus monkeys, only one out of the four
monkeys had convulsions, however, this same monkey did not display convulsive
activity when given a smaller dose weeks later or even the same dose one year later.69
The difference in convulsions in species could indicate that these are species-dependent
effects. As mentioned previously, the DOR is distributed in different areas of the spinal
cord in rodents versus primates. In rodents, the delta receptor is found dispersed in the
spinal cord, whereas it is limited to the superficial laminae of the spinal dorsal horn in
humans and non-human primates.
3.1.4 High-Throughput Virtual Screening Reasoning
High-throughput virtual screening (HTVS) is a useful computational process that
can screen for thousands of molecules that bind to a molecular target and can also
identify toxic or unfavorable pharmacodynamics and pharmacokinetic properties of these
compounds.70 Structure-based virtual screening (SBVS) is a HTVS approach that predicts
the interactions between ligands and proteins as a complex, ranking them by their affinity
to the receptor. The top hit compounds are then selected based on the desired parameters
and are then optimized to undergo preclinical and clinical trials. Computational methods
such as molecular modeling are used in the HTVS approach to speed up the drug
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discovery process by analyzing the interactions of multiple molecules in a shorter period
of time, which can look into interactions before the drug is even synthesized. SBVS is a
good technique due to its low cost, faster result time, and good results achieved.
3.1.5 Ensemble-Based Approaches
The flexibility of receptors is a challenge researchers face as binding sites usually
consist of 10-20 amino acid side-chains that have dozens of rotatable conformations,
which is larger than the rotatable torsions of a ligand.71 The movements of the backbone
can make this even worse by affecting multiple side chains. Using an ensemble-based
receptor technique combats this issue in HTVS and MD simulations by sampling the
degrees of freedom instead of traditional techniques using one receptor conformation
with a flexible ligand. It has been found in cases to also improve docking scores. With
previous studies it has been suggested that ensembles generated from simulations have
been closely similar in replicating the dynamics of proteins in NMR experiments.72, 73 It
is better to use a few specifically selected conformations as using too many could give
false results. In the case of virtual screening, using the top 10% of a library subset is more
efficient with this approach.71 Previous studies using ensemble-based virtual screening
have been successful in screening ligands against various drug targets.74, 75 The
integration of this ensemble-based technique helps to have a better understanding of the
structural dynamics of a receptor, have a better understanding of ligand-receptor
interactions which aids in discovering novel ligand binding modes, and helps to develop
better therapeutic molecules.76
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3.1.6 Experimental Overview
In the present study, we used MD simulations to probe the active conformation of
the DOR starting with the active crystal conformation (PDB ID: 6PT3) with the crystal
agonist DPI-287 (Figure 11). This agonist is highly selective towards the DOR and has
shown antidepressant effects with less convulsive properties than the other drugs in this
drug family in the rat forced swim test.77

Figure 11
Structural Organization of the Active Conformation of the DOR and Ligand
(A)

(B)

(C)
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Using the ensemble-based method, two representative conformations were identified
from the clustering and principal component analysis based on the MD simulation. These
two conformations and the crystal conformation were used to screen 17 million
compounds from the zinc database. As a result, 69 drugs were identified on the basis of
docking scores. These 69 complexes underwent MD simulations to assess their stability.
From this, 8 were identified that showed significantly improved MM-GBSA binding free
energy scores with high blood brain barrier (BBB) permeability and high gastrointestinal
(GI) absorption. This study helps to identify potential compounds to be further tested that
will aid in antinociception without addictive or convulsive properties for the DOR.
3.2 Methods
3.2.1 Virtual Screening Workflow Overview
Using the Zinc 15 drug-like library that contains 17 million entries, a virtual
screening workflow (VSW) was developed to identify lead agonists to the DOR. The
VSW is made up of ten steps that includes drug property prediction, molecular docking,
and molecular dynamics simulations (Figure 12).
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Figure 12
Virtual Screening Workflow
ZINC drug-like library (17M)
Receptor (6PT3) (3
conformations)
ADMET Filter (QikProp)

Glide HTVS Docking Top 10%

Glide SP Docking Top 10%

Glide XP Docking Top 10%

Diverse Structure (Canvas)

Pick Top 69 Compounds

Molecular Dynamics
(Desmond) (200ns)

Post Simulation Analysis

ADMET Prediction

Top 8 Compounds

Inputting the prepared protein structure and ligand library is the first step of the VSW. In
steps 2-5, the compounds were then filtered by drug property with docking and multiple
Glide docking score functions that have increasing accuracy (Glide HTVS, SP, and XP).
In the next step, a ligand similarity analysis was performed to identify different molecular
scaffolds. In step 7, the ligands that were removed were based on if they had a worse
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Glide XP score than the reference compound (PDB ID: 6PT3 ligand DPI-287) and/or if
they had more than one red flag in drug property (number of stars, from QikProp). The
top compounds were manually selected from the remaining compounds by maximizing
the number of molecular scaffolds (i.e. different ligand cluster IDs). The 200ns MD
simulations were carried out in step 8 which was then followed by the post simulation
analyses in step 9, including MMGBSA binding free energy calculation, simulation
interaction diagram analysis, and protein conformation clustering analysis. In the last
step, the ADMET (Absorption, Distribution, Metabolism, Excretion, and Toxicity)
prediction was used to examine the human oral bioavailability of potential drug
candidates. From this, the compounds with better MM-GBSA binding free energy than
the reference compound were selected and presented in the main text. The ten steps are
presented in detail in the following six modules.
1. Preparation of Protein and Ligand Library
The crystal structure (6PT3) of the active conformation of the DOR was prepared
and preprocessed using Maestro’s Protein Preparation Wizard.78 The charge state of the
preprocessed protein was optimized at pH 7. A restrained minimization was then
performed to relax the protein structure using OPLS3 force field.79 The 3D structures of
DPI-287 and the Zinc compounds were prepared using Maestro Elements. The 3D
structure of DPI-287 was extracted from the crystal structure (PDB ID: 6PT3) and the
Zinc compounds were downloaded from the Zinc15 database
(https://zinc15.docking.org/). The ionization/tautomeric states for the ligands were
generated at pH 7 using Maestro’s Epik tool based on the more accurate Hammet and
Taft methodologies.78 The lowest ionization/tautomeric state was selected and the
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geometry was then minimized to the most energetically favorable structure to relax the
structure of the ligand. A geometry optimization was utilized using quantum mechanics
in Jaguar as the final step.
2. Filtering and Docking
The prepared protein and ligand were merged into a complex to then be ran
through the Schrodinger Virtual Screening Interface using prefilters through Lipinski’s
Rule and filtered with ADMET risk parameter assessments through QikProp. The
receptor grid files were generated from the prepared receptors, in which the centroid of
the crystal ligand, DPI-287, was used to specify the active site. The prepared ligands
were docked into their corresponding generated grids using Glide XP scoring with default
procedures and parameters.79 In detail, the receptor grid required for the docking process
was generated using van der Waals scaling factor of 1 and partial charge cutoff 0.25.
Docking was performed using a ligand-centered grid using OPLS3 force field. Glide XP
Dock performed a comprehensive systematic search for the best receptor conformations
and orientations to fit the ligand. The docked poses were compared to the active crystal
complex (PDB ID: 6PT3) with an agonist to verify if the docked ligand poses were
reasonable. All ligands were bound within the binding pocket with DPI-287 binding
similar to the crystal ligand, providing a reasonable starting pose for later molecular
dynamic simulations. The binding pose can then be refined given the full conformation
flexibility in the simulations. The docking results comprised of 69 top compounds with
higher docking scores than the reference ligand (6PT3), indicating they all had high
affinity for the receptor.
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3. Ligand Similarity Clustering
The canvas program was used for the ligand similarity clustering. This program
uses pharmacophore fingerprinting and hierarchical clustering to further filter out top
compounds. Pharmacophore fingerprinting identified similar groups of compounds to
match the crystal structure.80 Hierarchical clustering was then utilized to form cluster
groups of similar compounds based on their docking score, binding affinity, drug
properties, and ligand similarities.81, 82 The poses were manually generated and evaluated
based on their binding score and similarity to known FDA-approved drugs. The top 69
compounds were then used for the MD simulations.
4. MD Simulation
4.1. MD Simulation System Setup
The 69 prepared receptor-ligand complexes were used to construct MD simulation
systems using the prepared and refined receptor-ligand complex from the Glide XP
docking, crystal structure (6PT3), and generated conformations as input files. Each
system was built using SPC as water solvent model83 using orthorhombic solvent box
with 6Å water buffer. The system was neutralized using Na+ and Cl- ions and were added
to maintain the salt concentration of 0.15 M NaCl. After the system was successfully
solvated, OPLS3 force field using Desmond System Builder79 was used to represent the
receptor-ligand.
4.2. Relaxation and Production Runs
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Using Desmond module, the system was first relaxed using the default relaxation
protocol for membrane proteins.84 This relaxation protocol consists of eight stages: 1).
Minimization with restraints on solute heavy atoms; 2). Minimization without any
restraints; 3). Simulation with heating from 0 K to 300 K, H2O barrier and gradual
restraining; 4). Simulation under the NPT ensemble (constant number of particles,
constant pressure of 1 bar and constant temperature of 300 K) with H2O barrier and with
heavy atoms restrained; 5). Simulation under the NPT ensemble with equilibration of
solvent and lipids; 6). Simulation under the NPT ensemble with protein heavy atoms
annealing from 10.0 kcal/mol to 2.0 kcal/mol; 7). Simulation under the NPT ensemble
with Cα atoms restrained at 2kcal/mol; and 8). Simulation for 1.5 ns under the NPT
ensemble with no restraints.
After the relaxation, each system was submitted to a 200 ns production run
conducted under the NPT ensemble for each of the systems using the default protocol. In
details, temperature was controlled by using the Nosé-Hoover chain coupling scheme85
with a coupling constant of 1.0 ps. Pressure was controlled using the MartynaTuckerman-Klein chain coupling scheme85 with coupling constant of 2.0 ps. M-SHAKE86
was applied to constrain all bonds connecting hydrogen atoms, enabling a 2.0 fs time step
in the simulation. The k-space Gaussian split Ewald method87 was used to treat longrange electrostatic interactions under periodic boundary conditions (charge grid spacing
of ~1.0 Å, and direct sum tolerance of 10-9). The cutoff distance for short-range nonbonded interactions was 9 Å, with the long-range Van der Waals interactions based on a
uniform density approximation. To reduce the computation, non-bonded forces were
calculated using an r-RESPA integrator88 where the short-range forces were updated
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every step and the long-range forces updated every three steps. The trajectories were
saved at 40.0 ps intervals for analysis.
5. Post Simulation Analysis
5.1. Simulation Interaction Diagram (SID) Analysis
Desmond SID tool was used to analyze the behavior and interaction of proteins
and ligands during the course of simulation including RMSD; protein-ligand contacts
including H-bonds, hydrophobic, ionic, and water-bridge contacts; secondary structure
changes and Root Mean Square Fluctuation (RMSF) measures. To check the convergence
of MD simulations, the protein Cα and ligand RMSD plots were investigated for each
trajectory. Relatively flat plots indicate that the complex systems have reached a steady
state.
5.2. Trajectory Clustering Analysis
Desmond trajectory clustering tool89 was used to group complex structures from
the last 100 ns simulation of each complex system. Backbone RMSD matrix was used as
structural similarity metric, the hierarchical clustering with average linkage was selected
as the clustering method. The merging distance cutoff was set to be 2Å. The centroid
structure (i.e. the structure having the largest number of neighbors in the structural
family) was used to represent the structural family.
5.3. Binding Energy Calculations and Decompositions
The surface-area-based Generalized Born model90, 91 was used to calculate the
ligand-binding affinities on the frames in the last 50 ns of each MD simulation with an
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implicit membrane solvation model (VSGB 2.0).92 Slab-shaped regions with a low
dielectric constant between 1 and 4 were excluded from the implicit membrane and were
assigned with the solvent (water) dielectric constant of 80. The MM-GBSA calculation
used an OPLS3 force field and the default Prime procedure.79 The OPLS3 force field
employs a CM1A-BCC-based charge model based on a combination of Cramer-Truhlar
CM1A charges93 with an extensive parameterization of bond charge correction terms
(BCC). This process begins with minimizing the receptor only, then the ligand only, and
then the receptor-ligand complex. Using equation 1, the MM-GBSA binding free energy
for each system was calculated from three separate simulations: ligand-only, receptoronly, and the receptor-ligand complex. Equation 2 contains 4 components: Van der Waals
interaction energy (VDW), hydrophobic interaction energy (SUR), electrostatic
interaction (GBELE), and the change of the conformation energy for the receptor and
ligand that were calculated based on equations 3 and 4.
∆𝐸 = 𝐸𝑐𝑜𝑚𝑝𝑙𝑒𝑥 − 𝐸𝑟𝑒𝑐_𝑓𝑟𝑒𝑒 − 𝐸𝑙𝑖𝑔_𝑓𝑟𝑒𝑒

(1)

∆𝐸 = ∆𝐸𝑣𝑑𝑤 + ∆𝐸𝑆𝑈𝑅 + ∆𝐸𝐺𝐵𝐸𝐿𝐸 + ∆𝐸𝑐𝑜𝑚𝑓𝑜𝑟𝑚𝑎𝑡𝑖𝑜𝑛

(2)

∆𝐸𝑥 = 𝐸𝑥_𝑐𝑜𝑚𝑝𝑙𝑒𝑥 − 𝐸𝑥_𝑟𝑒𝑐_𝑐𝑜𝑚𝑝𝑙𝑒𝑥 − 𝐸𝑥_𝑙𝑖𝑔_𝑐𝑜𝑚𝑝𝑙𝑒𝑥 , x= vdw, sur and gbele (3)
∆𝐸𝐶𝑜𝑚𝑓𝑜𝑟𝑚𝑎𝑡𝑖𝑜𝑛 = 𝐸𝑟𝑒𝑐_𝑐𝑜𝑚𝑝𝑙𝑒𝑥 +𝐸𝑙𝑖𝑔_𝑐𝑜𝑚𝑝𝑙𝑒𝑥 − 𝐸𝑟𝑒𝑐_𝑓𝑟𝑒𝑒 − 𝐸𝑙𝑖𝑔_𝑓𝑟𝑒𝑒

(4)

The MM-GBSA scoring function lacks the solute conformational entropy
contribution, which causes higher negative values when compared to actual values. It is
essential being able to rank a drug’s ability to target a receptor when it is used to rank
different drugs targeting receptors with comparable entropy values.94 MM-GBSA has
shown to be a powerful tool in ranking ligands supported by multiple studies.95-98
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6. ADMET Prediction
ADMET properties were predicted for the best ZINC compounds were performed
on the SwissADME web server (http://www.swissadme.ch/). The SwissADME server
was developed by the Swiss Institute of Bioinformatics and is used to provide
physiochemical descriptors, ADMET parameters, pharmacokinetic properties, and druglike small molecules to support drug discovery.99 In order to receive each compounds
ADMET properties, their respective SMILE codes were inserted into the webserver.
3.2.2 Normal Mode Analysis
The trajectory for the crystal complex (PDB ID: 6PT3) was used in the Normal
Mode Wizard in VMD100 to generate a principal component analysis of the top 10 normal
modes.
3.2.3 Dynamical Network Model
A dynamic network model, defined as a set of nodes connected by edges,97, 101-104
was generated using the individual trajectories of each system using the NetworkView
plugin41 in VMD.49 We first generated a contact map for each system of the top
compounds and the crystal complex that added an edge between nodes whose heavy
atoms interacted within a cutoff of 4.5Å for at least 75% of the MD simulation time. The
edge distance was derived from pairwise correlations103 in the contact map using the
program Carma105, which defines the probability of information transfer across a given
edge using the following equation:
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The edges in the dynamic network model are weighted (wij) between two nodes i and j
which uses the following calculation: wij = -log(|Cij|). The weight of the edge is
correlated with the probability for information to transfer across the edge between two
nodes. Because of this, a thicker edge is characterized as a higher probability of
information transfer. The network for each system was further grouped into communities,
or subnetworks based on groups of nodes with more frequent and stronger connection to
each other, by applying the Girvan-Newman algorithm to the original network.106 The
critical nodes that connect communities to each other were identified as well. Optimal
communication paths were generated between the ligand node and the molecular switch
residue number using the data from the molecular switches.
3.3 Results
3.3.1 Crystal Conformation Maintained Stability During MD Simulation
The crystal complex of the active conformation of the human DOR (PDB ID:
6PT3) with crystal agonist DPI-287 was used in the experiment to set the standard serve
as the control. DPI-287 was first docked back into the crystal conformation and resulted
in a similar binding pose with the crystal pose with a docking score of -8.6 kcal/mol,
validating the docking protocol. The docked complex was used as the input structure to
perform 1000 ns MD simulations to be further analyzed (Figure 13). First, the RMSD
checked for convergence, in which the last 200 ns show the system to have converged
with relatively flat plots. The secondary structure elements (SSE) shows the helices were
maintained during the simulation. The RMSF shows fluctuation in the intra- and
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extracellular loops, as well as the terminals, which are the most flexible parts of the
receptor. The 2D ligand-protein interactions shows the residues that interacted with the
ligand for at least 30% of the simulation, which shows mostly hydrophobic contacts and
some hydrogen bonding. Looking at the protein-ligand histogram shows the interacting
residues for the whole simulation. This corresponds with the 2D interactions where most
interactions with residues are hydrophobic or hydrogen bonding. Overall, the system was
shown to be stable and mimic the crystal structure with a stable binding pose.
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Figure 13
Simulation Interaction Diagrams After MD Simulation of the Crystal Structure

Note: (A) RMSD plot from MD simulation of 200ns. (B) Protein Secondary Structure
elements (SSE). Orange represents alpha helices, blue represents beta strands. (C) RMSF
graph of protein of the crystal complex structure. (D) 2D ligand-protein interaction
diagram from the MD trajectory. The residue displayed interacted with ligand for at least
30% of the simulation time. (E) Protein-ligand contacts during MD simulations.
Interaction fraction greater than 1 is because of multiple contacts on one residue.
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3.3.2 Crystal Complex Produces Other Conformations to Use For HTVS
The clustering analysis was done after the MD simulation to identify the
populated conformation for the trajectory. Each cluster conformation contains a
percentage of abundance based on the clustering algorithm in which a cutoff of 2% was
used. From this, there were two abundant clusters (75% and 24% respectively) produced
from the crystal conformation simulation and were compared to the crystal complex
(Figure 14).
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Figure 14
Superimposition of the Active Crystal DOR Structure With the Most Abundant
Conformations From the MD Simulations With Agonist DPI-287

Note. (A) DOR crystal conformation superimposed with the first abundant conformation
(yellow, 75%) in complex with agonist DPI-287 (orange) including ligand only view; (B)
DOR crystal conformation superimposed with the second abundant conformation (pink,
24%) in complex with agonist DPI-287 (green) including ligand only view; (C) DOR
crystal conformation superimposed with both abundant clusters and all ligand poses.

The two clusters slightly differ in conformation and the ligand binding pose from the
crystal conformation. In a more precise view, the binding pocket of each structure was
compared to the crystal pose (Figure 15).
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Figure 15
Predicted Binding Pocket of the Different DOR Conformations

Note. Structural alignment of crystal conformation (cyan) with (A) representative
conformation 1, (B) representative conformation 2, (C) both conformations.

In this view, differences can be seen in the receptor itself and also the side chains that
have adopted different rotamer states. Specific residues where the side chains differ the
most from the crystal in both clusters are N90, D95, D128, N131, N310, and Y318.
Using the normal mode analysis on the crystal MD simulation revealed the top two low
frequency vibrational modes differ from each other (Figure 16).
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Figure 16
Top 2 Low Frequency Vibrational Modes From the Normal Mode Analysis

Note Based on the MD simulation of the crystal conformation of the active DOR in
complex with agonist DPI-287. (A) Mode 1; (B) Mode 2.

This further validates the result of two cluster conformations that differ from the crystal
conformation and therefore can be used as additional conformations to use for HTVS.
Unweighted and weighted dynamic network models of the DPI-287/DOR system were
calculated as described in the methods section to decipher the allosteric signal
transmission pathway. The unweighted network model shows that their connections are
in good agreement. Quantifying the correlation between the nodes in the weighted
network model reveals the areas of the receptor that are in higher correlation to each
other. The system appears to have higher correlations between edges TM5 and TM6. A
community network model was generated using the weighted network model which
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grouped residues together that interact more frequently and stronger than to residues in
other communities (Figure 17).

Figure 17
Network Analysis

(A)

(C)

(B)

(D)
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There were 38 critical nodes identified for the crystal system from the community
analysis. These critical nodes were involved in signal transduction between different parts
of the receptor throughout the simulation and therefore, the critical residue information
was then cross referenced with experimentally reported mutagenesis data available on the
G-protein coupled receptor databank (GPCRdb) to see if the residues were involved in
the physical signal transduction. The DPI-287 system had 9 critical residues that were
also naturally occurring mutations (D95, Y129, M132, M142, R160, M186, A269, I282,
N310). It also had 3 critical residues that were mutations invitro (D95, W274, S312).
Optimal paths generated for the DPI-287/DOR system give insight into the molecular
signal transduction pathways involving the ligand. From the weighted network models,
the shortest pathways able to pass a signal from the ligand to the site of the molecular
switch (Tyrosine Toggle Switch: Y318) and the intracellular end of TM6 (Transmission
Switch: S255) were calculated as the optimal paths. DPI-287 has a direct optimal path for
the Transmission Switch (CWXP) through TM6 and another direct path for the Tyrosine
Toggle Switch (NPXXY) through TM7. The HTVS was then ran on all three
conformations (crystal conformation, cluster 1, cluster 2) of the active DOR for FDA
approved drugs and compounds from the zinc15 database of 17 million compounds.
Comparing the zinc compounds to the FDA approved drugs revealed that the zinc
compounds had significantly better docking scores, therefore, ruling out the use of the
FDA drugs. Each compound was docked back into the DOR binding pocket and had
similar poses to the crystal ligand. Using the docking score of the crystal ligand DPI-287
as a cutoff (-8.6 kcal/mol), the number of stars which tells how drug-like a compound is,
and the cluster ID which tells how similar molecule scaffolds are to each other, a total of

78

69 zinc compounds were chosen. These docked compounds also showed good binding
pose agreement with the crystal ligand. Out of the 69 compounds chosen, 32 were
targeted to the crystal conformation, 11 were targeted to the first abundant cluster, and 26
were targeted to the second abundant cluster. Each of the 69 compounds underwent 200
ns MD simulations. The MM-GBSA was calculated for each of the molecules to their
respective receptor conformation, including the crystal ligand DPI-287, to determine the
binding affinity for the receptor with more negative values indicating better binding
(Table B1). DPI-287 had an MM-GBSA of -90.2 kcal/mol which was used as the cutoff.
With the MM-GBSA as a determinate, another method was used to pick out the top
molecules, the SwissADME properties (Table B2). This tells the drugs predicted
properties in which high gastrointestinal (GI) absorption and blood brain barrier (BBB)
permeability were the major determinates. Also similar to the crystal ligand, having no
alerts was attractive as well due to having a low chance of false positives from occurring.
Considering all of this, 8 ligands were chosen as the top compounds (Table 5, Table 6).
Two of the molecules were targeting the crystal conformation, four were targeting the
first abundant cluster, and two were targeting the second abundant cluster. These 8
compounds were further analyzed.
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Table 5
Various Properties of the Top 8 Compounds Identified From Our Virtual Screening Work
Flow

Table 6
The Predicted Pharmacokinetics ADME Properties
Compound

GI
absorption

BBB
permeant

CYP1A2

CYP2C19

CYP2C9

CYP2D6

CYP3A4

Lipinksi
rule

PAINS

Brenk

Yes; 0
violation

0 alert

0 alert

0 alert

0 alert

0 alert

0 alert

0 alert

0 alert

0 alert

0 alert

0 alert

0 alert

0 alert

0 alert

0 alert

0 alert

0 alert

0 alert

Crystal Structure
(PDB ID:6PT3)

High

Yes

No

No

No

Yes

Yes

ZINC000020559278

High

Yes

Yes

No

No

Yes

Yes

ZINC000078515864

High

Yes

No

No

No

Yes

No

ZINC000025329384

High

Yes

No

No

No

Yes

Yes

ZINC000037556415

High

Yes

No

Yes

Yes

Yes

Yes

ZINC000827360794

High

Yes

No

No

No

Yes

Yes

ZINC000078648574

High

Yes

No

Yes

Yes

Yes

No

ZINC000057999653

High

Yes

Yes

Yes

Yes

Yes

Yes

ZINC000006664413

High

Yes

Yes

Yes

Yes

Yes

Yes

Yes; 0
violation
Yes; 0
violation
Yes; 0
violation
Yes; 0
violation
Yes; 0
violation
Yes; 0
violation
Yes; 0
violation
Yes; 0
violation

3.3.3 Top 8 Compounds Assume Steady State
Each zinc compound was calculated for the RMSD of their respective simulations
to check the convergence and if it has reached a steady state (Figure 18). The RMSD
analyzes the movement of the ligand the receptor during the simulation. In the case of all
8 compounds, it can be observed by the last 50 ns that they have converged by
approaching steady values. The protein RMSD has lower RMSD values and have
80

remained more stable in each of the complexes. The ligand RMSD indicated compounds
in which there are multiple fluctuations such as ZINC000025329384,
ZINC000037556415, and ZINC000078648574. The others remained more stable
throughout the simulation.

Figure 18
RMSD of the Top 8 Zinc Compounds

Note: Cα RMSD during 200 ns MD simulation in reference to the crystal active DOR
conformation (PDB ID: 6PT3).
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3.3.4 MD Simulations Improved the Binding Pose of the Top Eight Ligands
The Glide XP docking pose of each of the ligands were superimposed and
compared to the pose from the MD simulation (Figure 19). The simulation can
significantly alter the ligands original bound conformation to optimize the interactions
with the receptor. The simulation improved the binding pose of each of the top
compounds. This corresponds with the MM-GBSA results (Table 5) that was used to
estimate the binding free energy of the compounds where the binding interaction between
the protein-ligand complexes is specified by the free energy binding. The crystal ligand
was used as a control where its score was -90.2 kcal/mol. The top compounds picked had
significantly higher binding energy to the DOR with the lowest of the scores being -94.6
kcal/mol.
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Figure 19
Comparison of Glide XP Docking Pose (Blue) and MD Simulation Pose (Red) for the Top
8 Compounds

3.3.5 Protein-Ligand Interactions of Top Compounds to the DOR
The residues involved in the compounds binding to the receptor were analyzed as
described in the methods section with the Desmond Simulation Interaction Diagram. All
interacting residues to the top 8 compounds and crystal ligand are clearly tabulated in
Table 7.
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Table 7
Protein-Ligand Interactions During MD Simulations for the Top 8 Compounds From the
MD Simulations

The highest amount of hydrogen bonding was in compounds ZINC000078515864,
ZINC000006664413, and ZINC000020559278. ASP128 is the main residue involved in
hydrogen bonding in seven of the eight compounds and is also maintained in the crystal
ligand (Figure 20). ZINC000037556415, ZINC000827360794, ZINC000078648574,
ZINC000057999653, and ZINC000006664413 have the highest number of hydrophobic
contacts which the interaction of such generally involves hydrophobic amino acids and an
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aromatic or aliphatic group on the ligand. Ionic interactions were mainly observed in
ZINC000025329384 and ZINC000057999653. Water bridges occurred in all top 8
compounds with the exception of ZINC000078648574 which is the same compound that
did not show hydrogen bonding to residue ASP128. The majority of the compounds
showed higher hydrophobic interactions and hydrogen bonding in comparison to the
crystal structure, leading to higher GI absorption.
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Figure 20
Protein-Ligand 2D Interaction Diagrams From the MD Simulation for the Top 8
Compounds
ZINC000020559278

ZINC000827360794

ZINC000078515864

ZINC000025329384

ZINC000037556415

ZINC000078648574

ZINC000057999653

ZINC000006664413
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3.3.6 Secondary Structure Shows Maintained Helices
The protein SSE was monitored throughout the MD simulation where the plots
summarize the structure elements distribution by residue position throughout the protein.
The three categories are Alpha-helices, Beta-strands, and random coils. Alpha-helices are
mainly made up of hydrophobic residues that are located in the core of the protein and are
depicted by the orange sections. Beta-strands, however, contain both hydrophobic and
polar amino acids which are depicted by blue sections. The random coil is not one
specific shape of a polymer conformation, but a distribution of statistics of all chains
depicted by the white spaces in the plots. The secondary structure is more rigid than the
loop regions, inferring that they have less fluctuation.
3.3.7 RMSF Shows Fluctuation in Regions of the Protein With Respect to the Ligand
The RMSF calculated the fluctuation of the protein in complex with each
compound using the Cα atom. Specifically, the changes in the protein backbone were
observed during the simulation (Figure B9). Higher values depicted by peaks are areas of
the protein that fluctuate the most, such as the N- and C-terminals as well as the intraand extracellular loops. ZINC000037556415 showed the greatest fluctuation at nearly 5Å
around residue 200 which is located in extracellular loop 2. All compounds showed
similar fluctuation at the same residue positions between 1-3Å. A small fluctuation from
ZINC000078648574 and ZINC000020559278 was observed around residue 250. Using
the crystal structure as a positive control, each complex showed the same or higher
residual fluctuation throughout the simulations.
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3.3.8 Network Analysis Helped to Understand Communications Among Different
Regions of the DOR
Unweighted and weighted network models of the DPI-287/DOR system and the
top compound systems were calculated as described in the methods section to decipher
the allosteric signal transmission pathway. The comparison of the unweighted network
models between the systems show that their connections are in good agreement.
Quantifying the correlation between the nodes in the weighted network model reveals
similarities observed between the systems. All systems appear to have higher correlations
between edges TM5 and TM6. Community network models were generated using the
weighted network model which grouped residues together that interact more frequently
and stronger than to residues in other communities. The systems that seem to
communicate more similarly to the crystal complex are ZINC000020559278,
ZINC000078515864, ZINC000827360794, ZINC000078648574, ZINC000057999653,
and ZINC000006664413. The basis for the similarity is that the intracellular portion of
TM5 and TM6 are in the same community represented by one single color. Another thing
that was observed in most of the similar systems is that the extracellular portion of TM6
and TM7 belong to the same community while the same region in TM5 belongs to a
different community. This trend occurred in ZINC000078515864, ZINC000827360794,
and ZINC000078648574. The systems that had the most similarities in critical nodes with
the crystal system are ZINC000020559278 with 11 of the same critical nodes,
ZINC000078515864 with 13, and ZINC000078648574 with 11 (Table B3). When
calculating the optimal paths of the Transmission and Toggle Switch for each of the top
compounds, multiple systems showed great similarities to the crystal complex (Figure 21
& Table B4). ZINC000025329384 shared every residue as the crystal with the
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Transmission Switch pathway and two out of the four residues of the Toggle Switch
pathway. ZINC000020559278, ZINC000078515864, and ZINC000037556415 also had
many similar residues to the crystal complex with the Transmission Switch and Toggle
Switch. ZINC000827360794 had the most residues similar to the crystal with the Toggle
Switch.
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Figure 21
Optimal Signal Transduction Pathway of the Transmission Switch and the Toggle Switch

Note: Transmission switch (pink nodes) and the Toggle switch (orange nodes) starting
from the ligand of each of the top 8 compounds.
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3.4 Discussion
The opioid epidemic has brought to light of the need for better opioid alternatives
in public health all around the world. The continued rise of opioid addiction and overdose
will not stop until there are better therapeutic agents available. Researchers and scientists
have discovered that the DOR shows potential in not only pain management, but also in
neurological and psychiatric disorders. Agonists targeting the DOR are strongly believed
to not display addictive or dependence properties, such as MOR agonists, having the
potential to help combat the addictive opioid crisis today.
Though previous studies have been done on the DOR, none to our best knowledge
have ever utilized multiple conformations from MD simulations for HTVS. MD
simulations are able to probe deeper into interactions and dynamics that happen in a
system that cannot be obtained from a crystal structure alone. Sampling the
conformations from the active state DOR and using them for HTVS offers an opportunity
to find better potential agonists to be of therapeutic use. Running long MD simulations on
each of the top compounds takes it a step further by predicting if the compounds bound to
the DOR will remain stable and looking into any protein-ligand interactions that may
occur. Here we present the first study using ensemble-based HTVS to discover potential
agonists to target the DOR.
Based on our findings using the bioinformatics tools and drug similarity search,
we analyzed compounds from Zinc15 and targeted novel agonists of the DOR using the
virtual screening workflow which gave us a promising top 69 hits (32 from crystal
conformation, 11 from cluster conformation 1, and 26 from cluster conformation 2).
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These top 69 compounds were then further validated and compressed to eight of the
agonists, which were further validated by the MM-GBSA score of binding free energy,
MD simulation, and predicted drug ADME properties. The MM-GBSA score helped to
investigate the binding interaction between the ligands and protein. The predicted drug
ADME properties helped to specify if the compounds were highly (GI) absorbent as well
as BBB permeant. These were the properties most valued due to opioids coming in an
oral form and the receptors being located in areas of the brain. Without these specific
properties, the compounds could be ruled out.
The protein-ligand interaction further confirmed the top potential agonists. The
large dataset and extended HTVS method portray the best interactions between ligands to
form a complex with a molecular target. The adverse effects and related articles of the
selected compounds were checked through CAS Scifinder and PubChem, where the
compounds showed no adverse effects. Out of the top eight, ZINC000057999653 is
patented to be useful for altering the lifespan of eukaryotic organisms. These results
further validate the top hits to be potential agonists.
The use of dynamic network models based on MD simulations data has shown to
be efficient in extracting correlated motions, allosteric signals, and signal transduction
networks within complex systems. The correlated motions are thought to be linked to
their activity which is normally difficult to accurately distinguish through visualization of
the MD simulations alone.107, 108 In addition, the communities that are generated with the
dynamic network are highly correlated and provide insight into the overall
communication network from ligand binding.107, 109, 110 In our study, the dynamic network
analysis aided in identifying similar communication systems between the crystal DPI-287
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and top compound systems. These similarities became more apparent when comparing
the weighted networks that base their correlated motion in the simulation trajectories to
the connections between nodes in the networks. The community models show that
compound systems of ZINC000078515864, ZINC000827360794, and
ZINC000078648574 communicate the most similar to the DPI-287 system. This analysis
highlights how the structural differences of the ligands can have similar or different
dynamics to the DOR due to the grouping of communities based on residues that interact
strongly and frequently with one another.
Based on the results, the potential binding and agonistic effects of the top eight
compounds are indicated. Ensemble-based structure HTVS is a useful approach to find
potential molecules that could target the binding pocket of the DOR. After examining 17
million Zinc15 compounds using structure-based HTVS methods, the most potential hits
were validated by MD simulations. This study has the potential to assist in the efforts to
aid in the opioid epidemic. Experimental studies can be conducted on these compounds to
help in the efforts of opioid addiction.
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Appendix A
To Probe the Activation Mechanism of the Delta Opioid Receptor by an Agonist
ADL5859 Started from Inactive Conformation Using Molecular Dynamic
Simulations
Table A1
RMSD Comparison
Type

Traj
#
1

ADL5859

2
3
4

5

Naltrindole

6

Cluster
ID
1 (52%)
2 (30%)
3 (17%)
1 (98%)
1 (90%)
2 (11%)
1 (43%)
2 (32%)
3 (20%)
4 (5%)
5 (1%)
1 (56%)
2 (43%)
1 (76%)
2 (22%)

Whole Protein (Å)
4N6H
6PT3
3.4
2.5
2.1
3.0
3.1
2.4
2.5
3.1
2.3
3.1
2.8
2.9
2.4
2.9
2.4
3.3
2.6
2.9
2.7
2.9
3.6
2.7
2.8
2.7
2.2
3.3
3.3
2.8
2.3
3.0

7TMD (Å)
4N6H
6PT3
2.8
2.2
1.8
2.7
2.5
2.2
2.1
2.6
1.9
2.6
2.4
2.6
2.1
2.4
1.9
2.7
2.0
2.3
1.7
2.3
2.9
2.1
2.5
2.4
1.7
2.8
2.6
2.4
1.9
2.5

TM6 (Å)
4N6H 6PT3
4.1
3.4
2.0
4.2
3.3
2.9
1.7
4.6
2.3
3.8
4.5
4.2
2.5
3.4
2.2
4.5
2.4
3.5
2.2
3.6
5.8
2.8
3.1
3.4
2.5
4.9
3.9
3.2
2.0
3.9

1

1 (100%)

3.1

3.4

2.7

3.0

1.8

5.5

2

1 (100%)

3.3

3.1

2.8

2.8

2.9

5.0

3

1 (100%)

3.2

3.3

2.7

2.9

2.4

4.9
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Table A2
Conserved Molecular Switches
Traj
#

Cluster
ID

1

1 (52%)
2 (30%)
3 (17%)
1 (98%)
1 (90%)
2 (11%)
1 (43%)
2 (32%)
3 (20%)
4 (5%)
5 (1%)
1 (56%)
2 (43%)
1 (76%)
2 (22%)
1
(100%)
1
(100%)
1
(100%)

ADL5859

2
3
4

5
6
Naltrindole

1
2
3

Distance (Å)
Toggle
(NPXXY)
Y3187.53-Y3187.53
1.1
1.4
1.4
1.5
1.7
1.1
2.2
1.8
1.5
0.2
1.1
0.6
0.4
0.5
1.5
1.5

Distance (Å)
Transmission
(CWXP)
S2496.23-S2496.23
9.4
6.9
10.3
1.3
6.0
9.2
1.7
2.5
2.4
1.3
13.9
6.2
2.5
10.6
5.9
3.0

Distance (Å)
Ionic Lock
(DRY)
R1463.50-T2606.34
9.3
5.9
2.3
3.9
6.1
6.7
7.8
7.2
7.4
6.7
6.5
5.8
6.4
4.2
6.1
3.8

1.4

3.8

4.4

1.5

3.8

3.7
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Figure A1
Solved Crystal Structures of the Human DOR With Fusion Proteins
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Figure A2
Sequences of Full-Length Crystal Human Delta Opioid Receptor (PDB ID: 4N6H)
(P41143)

107

Figure A3
Protein and Ligand RMSD of the DOR/ADL5859 Agonist System
A

B

C

D

E

F

G
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Figure A4
Protein and Ligand RMSD of the DOR/Naltrindole Antagonist System
A

B

C

D
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Figure A5
Receptor RMSDs From Individual DOR-Agonist-ADL5859 Simulation Systems Against
the Two Solved Crystal Receptor Structures

110

111

Figure A6
Receptor RMSDs From Individual DOR-Antagonist-Naltrindole Simulation Systems
Against the Two Solved Crystal Receptor Structures

112

Figure A7
Representative Structure of Each DOR-Agonist-ADL5859 Cluster and Its Comparison
With the Inactive and Active Solved Crystal Structure

113

114

115
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Figure A8
Representative Structure of Each DOR-Antagonist-Naltrindole Cluster and Its
Comparison With the Inactive and Active Solved Crystal Structure
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Figure A9
Protein Secondary Structure Comparison
N

ECL2

ECL1
TM1

TM2

TM4

TM5

TM6
ICL3

ICL2

Naltrindole (Antagonist)

ADL5859 (Agonist)

ICL1

TM3

ECL3
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TM7
C

Figure A10
Protein-Ligand 2D Interaction Diagram
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Figure A11
Protein-Ligand 2D Interaction Diagram

120

Figure A12
Protein-Ligand Interactions
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Figure A13
Protein-Ligand Interactions

122

Figure A14
The RMSF of the ADL5859 System
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Figure A15
The RMSF of the Naltrindole System
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Figure A16
Ligand RMSF Values For ADL5859
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Figure A17
Ligand RMSF Values For Naltrindole

126

Figure A18
Molecular Switches of ADL5859 (Trj 1 Cluster 1)
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Figure A19
Molecular Switches of ADL5859 (Trj 1 Cluster 3)
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Figure A20
Molecular Switches of ADL5859 (Trj 3 Cluster 2)

129

Figure A21
Molecular Switches of ADL5859 (Trj 4 Cluster 5)
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Figure A22
Molecular Switches of ADL5859 (Trj 6 Cluster 1)
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Figure A23
Molecular Switches of Naltrindole (Trj 1)

132

Figure A24
Molecular Switches of Naltrindole (Trj 2)

133

Figure A25
Molecular Switches of Naltrindole (Trj 3)
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Figure A26
Plots Showing Atomic (1-4) and Center of Mass (5-27) Distances Between Selected
Residues of Human DOR in the Agonist and Antagonist Bound DOR Systems
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137
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139

140

Figure A27
Top 10 Low Vibrational Modes From the NMA Based on the Agonist ADL5859 Complex
System in the First Trajectory (A) and Sixth Trajectory (B)
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144

Figure A28
Top 10 Low Vibrational Modes From the NMA Based on the Antagonist Naltrindole
Complex System in the First (A), Second (B), and Third Trajectory (C)
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Appendix B
To Probe Activation Mechanism of Agonist DPI-287 to Delta Opioid Receptor and
Novel Agonists to Using Ensemble-Based Virtual Screening with Molecular
Dynamics Simulations
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Table B1
Detailed Information Regarding Various Properties From the Glide XP Docking and MD
Simulations of the Compounds

150
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Table B2
The Predicted ADME Properties for Top Compounds
Structure

Compound

GI
absorption

BBB
permeant

CYP1A2

CYP2C19

CYP2C9

CYP2D6

CYP3A4

Lipinksi rule

PAINS

Brenk

Yes

Yes

Yes; 0
violation

0 alert

0 alert

Yes

Yes

0 alert

0 alert

No

No

Yes

0 alert

0 alert

No

No

No

0 alert

0 alert

Crystal Structure
(PDB ID:6PT3)

High

Yes

No

No

No

CC

ZINC000020559278

High

Yes

Yes

No

No

CC

ZINC000014242201

Low

No

No

No

CC

ZINC000562639987

High

No

No

No

CC

ZINC000071763967

High

Yes

No

No

No

No

No

CC

ZINC000067947687

High

Yes

Yes

No

No

Yes

No

CC

ZINC000634950507

High

Yes

No

No

No

No

No

CC

ZINC000072227493

High

Yes

Yes

Yes

Yes

No

No

CC

ZINC000257262766

High

No

No

No

No

Yes

Yes

CC

ZINC000006645700

High

Yes

Yes

Yes

No

Yes

No

CC

ZINC000082157638

High

No

No

No

No

No

No

CC

ZINC000091782363

Low

No

No

No

No

No

No

CC

ZINC000091595762

High

Yes

No

No

No

No

No

CC

ZINC000067558896

High

No

No

No

No

No

No

CC

ZINC000757213857

High

No

No

No

No

No

No

CC

ZINC000218867772

High

Yes

No

No

No

No

No

CC

ZINC000013637398

High

No

Yes

Yes

No

No

Yes

CC

ZINC000078515864

High

Yes

No

No

No

Yes

No

CC

ZINC000014538415

High

No

No

No

No

No

No

CC

ZINC000218873420

High

No

Yes

No

No

No

No

CC

ZINC000001743629

High

Yes

Yes

Yes

Yes

Yes

No

Yes; 0
violation
Yes; 0
violation
Yes; 0
violation
Yes; 0
violation
Yes; 0
violation
Yes; 0
violation
Yes; 0
violation
Yes; 0
violation
Yes; 0
violation
Yes; 0
violation
Yes; 0
violation
Yes; 0
violation
Yes; 0
violation
Yes; 0
violation
Yes; 0
violation
Yes; 0
violation
Yes; 0
violation
Yes; 0
violation
Yes; 0
violation

1 alert:
catechol_A
1 alert:
catechol_A

1 alert: catechol
1 alert: catechol

0 alert

0 alert

0 alert

0 alert

0 alert

0 alert

0 alert

0 alert

0 alert

0 alert

0 alert

1 alert: hydantoin

0 alert

0 alert

0 alert

0 alert

0 alert

0 alert

0 alert

0 alert

0 alert

1 alert:
thiocarbonyl_group

0 alert

0 alert

0 alert

0 alert

0 alert

0 alert

Yes; 0
violation

0 alert

0 alert

CC

ZINC000028295259

High

Yes

No

No

No

No

No

Yes; 0
violation

0 alert

0 alert

CC

ZINC000014536536

High

No

No

No

No

No

No

Yes; 0
violation

0 alert

0 alert

No

Yes; 0
violation

0 alert

0 alert

CC

ZINC000147095213

High

Yes

Yes

No

No

No

CC

ZINC000095698957

Low

No

No

Yes

No

No

No

Yes; 0
violation

0 alert

0 alert

CC

ZINC000014888594

High

Yes

No

No

No

No

No

Yes; 0
violation

0 alert

0 alert

No

Yes; 0
violation

0 alert

1 alert: phthalimide

0 alert

2 alerts: imine_1,
imine_2

CC

ZINC000015080658

High

No

No

No

No

No

CC

ZINC000096027748

High

No

No

No

No

No

No

Yes; 0
violation

CC

ZINC000067675691

High

No

No

No

No

No

No

Yes; 0
violation

0 alert

0 alert

Yes

Yes; 0
violation

0 alert

1 alert:
isolated_alkene

CC

ZINC000011691661

High

No

Yes

Yes

Yes

No

CC

ZINC000096312018

High

Yes

Yes

Yes

Yes

Yes

Yes

Yes; 0
violation

0 alert

0 alert

CC

ZINC000248261142

High

Yes

Yes

No

No

Yes

No

Yes; 0
violation

0 alert

0 alert

Yes

Yes; 0
violation

0 alert

1 alert: nitro_group

CC

ZINC000036160706

High

No

No

No

Yes
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No

C1

ZINC000025329384

High

Yes

No

No

No

Yes

Yes

Yes; 0
violation

0 alert

0 alert

C1

ZINC000037556415

High

Yes

No

Yes

Yes

Yes

Yes

Yes; 0
violation

0 alert

0 alert

C1

ZINC000095456365

High

No

No

Yes

Yes

Yes

Yes

Yes; 0
violation

0 alert

0 alert

C1

ZINC000225318193

High

Yes

Yes

Yes

No

No

No

Yes; 0
violation

0 alert

0 alert

No

Yes; 0
violation

0 alert

0 alert

Yes

Yes; 0
violation

0 alert

0 alert

1 alert:
catechol_A

1 alert: catechol

C1
C1

ZINC000299770618
ZINC000827360794

High
High

No
Yes

Yes
No

No
No

No
No

Yes
Yes

C1

ZINC000035373220

High

No

No

No

Yes

No

No

Yes; 0
violation

C1

ZINC000072430969

High

Yes

Yes

Yes

Yes

Yes

Yes

Yes; 0
violation

0 alert

0 alert

C1

ZINC000078648574

High

Yes

No

Yes

Yes

Yes

No

Yes; 0
violation

0 alert

0 alert

No

Yes; 0
violation

0 alert

0 alert

Yes

Yes; 0
violation

0 alert

1 alert: triple_bond

Yes

Yes; 0
violation

0 alert

0 alert

Yes

Yes; 0
violation

0 alert
1 alert:
ene_six_het_A

C1
C1
C2
C2

ZINC000005344596
ZINC000069348668
ZINC000057999653
ZINC000002877267

High
High
High
High

Yes
Yes
Yes
No

No
Yes
Yes
Yes

No
Yes
Yes
Yes

Yes
Yes
Yes
Yes

No
Yes
Yes
Yes

0 alert
2 alerts:
michael_acceptor_1,
michael_acceptor_4
1 alert:
thiocarbonyl_group

C2

ZINC000408693879

High

No

No

No

Yes

No

Yes

Yes; 0
violation

C2

ZINC000000880008

High

No

No

Yes

Yes

Yes

Yes

Yes; 0
violation

0 alert

Yes; 0
violation

0 alert

0 alert

0 alert

1 alert: imine_1

0 alert

1 alert:
thiocarbonyl_group

C2

ZINC000006664413

High

Yes

Yes

Yes

Yes

Yes

Yes

C2

ZINC000001408226

High

Yes

Yes

No

No

No

No

C2

ZINC000001045477

Low

No

Yes

Yes

Yes

Yes

No

C2

ZINC000005493735

High

No

No

Yes

Yes

No

Yes

0 alert

0 alert

C2

ZINC000001641702

High

Yes

Yes

Yes

Yes

Yes

No

Yes; 0
violation

0 alert

0 alert

C2

ZINC000000302628

High

Yes

Yes

Yes

No

No

No

Yes; 0
violation

0 alert

0 alert

Yes

Yes; 0
violation

0 alert

0 alert

No

Yes; 0
violation

0 alert

0 alert

C2
C2

ZINC000095418373
ZINC000006750553

High
High

No
Yes

Yes
Yes

Yes
Yes

Yes
No

Yes
Yes

Yes; 0
violation
Yes; 1
violation:
MLOGP>4.15
Yes; 0
violation

C2

ZINC000097002851

High

No

Yes

No

No

Yes

No

Yes; 0
violation

0 alert

0 alert

C2

ZINC000005776998

High

No

No

No

No

Yes

No

Yes; 0
violation

1 alert:
indol_3yl_alk

0 alert

C2

ZINC000004663101

High

Yes

Yes

Yes

No

Yes

No

Yes; 0
violation

1 alert:
anil_alk_ene

1 alert:
isolated_alkene

No

Yes; 0
violation

0 alert

2 alerts: imine_1,
imine_2

0 alert

1 alert:
thiocarbonyl_group

1 alert:
ene_five_het_B

1 alert:
michael_acceptor_1

0 alert

1 alert:
michael_acceptor_1

C2

ZINC000005604766

High

No

Yes

Yes

No

No

C2

ZINC000225173433

High

No

Yes

Yes

Yes

No

Yes

C2

ZINC000034720963

High

No

Yes

Yes

Yes

No

No

C2

ZINC000409066936

High

Yes

Yes

Yes

Yes

Yes

Yes
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Yes; 0
violation
Yes; 1
violation:
MLOGP>4.15
Yes; 0
violation

C2

ZINC000014750115

High

No

No

No

No

No

No

Yes; 0
violation

0 alert
1 alert:
indol_3yl_alk

0 alert

0 alert

C2

ZINC000059677349

High

Yes

Yes

Yes

No

Yes

Yes

Yes; 0
violation

C2

ZINC000002690402

Low

No

No

No

Yes

No

Yes

Yes; 0
violation

0 alert

1 alert:
thiocarbonyl_group

C2

ZINC000020572602

High

No

No

No

Yes

No

Yes

Yes; 0
violation

1 alert:
hzone_phenol_B

1 alert: imine_1

No

Yes; 0
violation

0 alert

1 alert: imine_1

0 alert

1 alert: hydantoin

0 alert

0 alert

C2

ZINC000408729576

High

No

No

No

No

No

C2

ZINC000009660785

High

No

No

No

Yes

Yes

Yes

Yes; 0
violation

C2

ZINC000334160398

High

No

No

No

Yes

Yes

Yes

Yes; 0
violation

154

Table B3
Critical Nodes Identified From the Network Analysis or the DPI-287/DOR System and
the Top 8 Compound Systems
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Table B4
The Optimal Path of the Transmission and Tyrosine Toggle Switch Generated From the
Network Analysis for the Crystal Complex and the Top 8 Compounds
Molecular Switch Optimal Path
C1 01
C1 02
C1 06
C1 09
Transmission Switch
Ligand Ligand Ligand
Ligand Ligand
W274
W274
W274
I304
V281
F270
F270
F270
L306
I279
V266
G268
V267
C273
A275
M262
L264
V265
A269
V271
R258
R261
M262
V265
G268
S255
R258
R258
M262
V265
S255
S255
R258
R261
S255
R258
S255
6 total
7 total
7 total
8 total
9 total
4 same 7 same 4 same
2 same 4 same

CC1

CC17

Ligand
Y308
S311
N314
Y318
4 total
2 same

Ligand
Y308
N310
N314
Y318
4 total
3 same

crystal

CC1

Ligand
W274
F270
G268
L264
R261
R258
S255

Ligand
W274
F270
V266
M262
R258
S255

7 total

6 total
4 same

crystal
Ligand
G307
N310
N314
Y318
4 total

CC17

C1 01
C1 02
C1 06
Tyrosine Toggle Switch
Ligand Ligand
Ligand
S311
S311
Y308
N314
P315
N310
Y318
Y318
N314
Y318
3 total
3 total
4 total
2 same 1 same
3 same
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C2 01

C2 05

Ligand
Y308
S312
N314
Y318
M262
R258
S255

Ligand
N131
F133
F137
T140
V144
R146
I259
S255

7 total
2 same

8 total
1 same

C1 09

C2 01

C2 05

Ligand
S311
N314
Y318

Ligand
Y308
S312
N314
Y318
4 total
2 same

Ligand
S311
N314
Y318

3 total
2 same

3 total
2 same

Figure B1
Top 10 Low Vibrational Modes From the NMA Based on the Active Conformation DOR
Agonist DPI-287 System
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Figure B2
Top 10 From the FDA Approved Drug Compounds for the Crystal Conformation
No
1

FDA approved drugs/ Structure/
Docking score
Lobivon; Nebivolol

No
6

FDA approved drugs/
Structure/ Docking score
Eluxadoline

7

Docking Score: -7.297 kcal/mol
Oxamniquine; Mansil

Docking Score: -8.467 kcal/mol

2

Lanreotide

Docking Score: -7.202 kcal/mol

3

Docking Score: -8.037 kcal/mol
Dobuject; Dobutamine

8

Hydroxyethyl cellulose

Docking Score: -7.638 kcal/mol
4

Lercanidipine

9

Docking Score: -7.132 kcal/mol
Terbutaline; Brethaire

5

Docking Score: -7.504 kcal/mol
Nylidrin; Arbid

10

Docking Score: -7.054 kcal/mol
Fenoterol; Alveofen

Docking Score: -7.482 kcal/mol
Docking Score: -6.965 kcal/mol
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Figure B3
Cα RMSD of the Top Zinc Compounds During 200ns MD Simulation in Reference to the
Crystal Active Conformation
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Figure B4
Comparison of 32 Zinc Compounds for the Crystal Conformation in the Docked Pose
(Blue) and the MD Simulation Pose (Red)
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Figure B5
Comparison of 11 Zinc Compounds for the First Representative Structure From the MD
Crystal Conformation in the Docked Pose (Blue) and the MD Simulation Pose (Red)
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Figure B6
Comparison of 26 Zinc Compounds for the Second Representative Structure From the
MD Crystal Conformation in the Docked Pose (Blue) and the MD Simulation Pose (Red)
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Figure B7
Protein-Ligand Contacts During MD Simulations for the Top 8 Compounds
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Figure B8
Protein Secondary Structure Elements (SSE) of the Receptor in Complex With the Top 8
Compounds
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Figure B9
The Cα Root Mean Square Fluctuation (RMSF) of the Receptor in Complex With the Top
8 Ligands
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